[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 119
11. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, Abaan OD, Chou TH, Dakshanamurthy S, Brown ML, Uren A, Toretsky JA: A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med; 2009 Jul;15(7):750-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma.
  • Ewing's sarcoma family tumors (ESFTs) contain a characteristic t(11;22) translocation leading to expression of the oncogenic fusion protein EWS-FLI1.
  • [MeSH-major] Antineoplastic Agents / pharmacology. DEAD-box RNA Helicases / metabolism. Indoles / pharmacology. Neoplasm Proteins / metabolism. Oncogene Proteins, Fusion / antagonists & inhibitors. Sarcoma, Ewing / drug therapy. Transcription Factors / antagonists & inhibitors

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Protein Sci. 2000 Sep;9(9):1753-73 [11045621.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10149-54 [18626011.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22317-22 [11301318.001]
  • [Cites] Anal Biochem. 2002 Sep 15;308(2):364-72 [12419351.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15105-15 [12560328.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):685-94 [12951587.001]
  • [Cites] Semin Cancer Biol. 2003 Aug;13(4):275-81 [14563122.001]
  • [Cites] Biochemistry. 2003 Dec 2;42(47):13787-99 [14636045.001]
  • [Cites] Blood. 2004 Jan 1;103(1):229-35 [12946992.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17134-41 [14769796.001]
  • [Cites] Eur J Biochem. 2004 Sep;271(18):3741-51 [15355351.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4135-9 [15483023.001]
  • [Cites] Biochemistry. 2004 Oct 26;43(42):13579-89 [15491164.001]
  • [Cites] Nature. 1992 Sep 10;359(6391):162-5 [1522903.001]
  • [Cites] J Cell Sci. 1993 Jun;105 ( Pt 2):481-8 [8408279.001]
  • [Cites] N Engl J Med. 1994 Aug 4;331(5):294-9 [8022439.001]
  • [Cites] J Clin Invest. 1997 Jan 15;99(2):239-47 [9005992.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1107-12 [9323138.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4947-52 [9389713.001]
  • [Cites] Nat Genet. 1998 Jul;19(3):254-6 [9662397.001]
  • [Cites] Oncogene. 1998 Aug 6;17(5):603-10 [9704926.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13709-13 [9811865.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] Cancer Cell. 2005 May;7(5):457-68 [15894266.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6199-206 [16024621.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8984-92 [16204072.001]
  • [Cites] J Comput Chem. 2005 Dec;26(16):1668-88 [16200636.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5574-81 [16740692.001]
  • [Cites] Nat Struct Mol Biol. 2006 Jun;13(6):509-16 [16680162.001]
  • [Cites] Mol Cell Proteomics. 2006 Jul;5(7):1212-23 [16571897.001]
  • [Cites] Nucleic Acids Res. 2006;34(14):3938-46 [16914450.001]
  • [Cites] Trends Biotechnol. 2006 Oct;24(10):435-42 [16876893.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):479-84 [17202261.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):233-45 [17361217.001]
  • [Cites] J Proteome Res. 2007 May;6(5):1882-98 [17391014.001]
  • [Cites] Cancer Cell. 2007 May;11(5):421-9 [17482132.001]
  • [Cites] Mol Cell. 2007 May 25;26(4):523-37 [17531811.001]
  • [Cites] Nat Rev Drug Discov. 2007 Nov;6(11):881-90 [17971784.001]
  • [Cites] Leuk Res. 2008 Apr;32(4):633-42 [17875318.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6004-9 [18413612.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1634-42 [11038348.001]
  • (PMID = 19584866.001).
  • [ISSN] 1546-170X
  • [Journal-full-title] Nature medicine
  • [ISO-abbreviation] Nat. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA088004-08; United States / NCI NIH HHS / CA / R01CA138212; United States / NCI NIH HHS / CA / R01CA133662; United States / NCI NIH HHS / CA / R01 CA133662; United States / NCI NIH HHS / CA / P01 CA47179; United States / NCI NIH HHS / CA / R01 CA138212; United States / NCI NIH HHS / CA / P30 CA051008; United States / NCI NIH HHS / CA / R01 CA138212-01; United States / NCI NIH HHS / CA / R01 CA088004; United States / NCI NIH HHS / CA / T32 CA009686; United States / NCI NIH HHS / CA / R01 CA133662-01A2; United States / NCI NIH HHS / CA / P01 CA047179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / EWS-FLI fusion protein; 0 / Indoles; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA-Binding Protein EWS; 0 / Transcription Factors; 0 / YK 4-279; EC 3.4.22.- / Caspase 3; EC 3.6.1.- / DHX9 protein, human; EC 3.6.4.13 / DEAD-box RNA Helicases
  • [Other-IDs] NLM/ NIHMS116382; NLM/ PMC2777681
  •  go-up   go-down


12. Dittrich C, Zandvliet AS, Gneist M, Huitema AD, King AA, Wanders J: A phase I and pharmacokinetic study of indisulam in combination with carboplatin. Br J Cancer; 2007 Feb 26;96(4):559-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / pharmacokinetics. Carcinoma / drug therapy. Neoplasms / drug therapy. Sarcoma / drug therapy. Sulfonamides / pharmacokinetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Mar 15;88(6):1336-46 [10717614.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6502-8 [17085665.001]
  • [Cites] Invest New Drugs. 2001;19(3):219-27 [11561678.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3508-21 [12177112.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Sep;50(3):243-50 [12203107.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):4065-73 [12351604.001]
  • [Cites] Anal Chem. 2003 May 1;75(9):2159-65 [12720356.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] Cancer Chemother Pharmacol. 1982;9(3):140-7 [6761010.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;27(5):409-12 [1999004.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):433-7 [1740682.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2112-7 [8229125.001]
  • [Cites] Eur J Cancer. 1994;30A(5):710-3 [8080692.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1860-70 [7543559.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 9):63-6 [7644931.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2054-60 [8683236.001]
  • [Cites] Semin Oncol. 1996 Oct;23(5 Suppl 12):19-21 [8941406.001]
  • [Cites] Rapid Commun Mass Spectrom. 2004;18(23):2839-48 [15517526.001]
  • [Cites] Arch Toxicol. 2005 Jul;79(7):406-13 [15798913.001]
  • [Cites] J Pharmacokinet Pharmacodyn. 2006 Oct;33(5):543-70 [16946998.001]
  • [Cites] N Engl J Med. 2006 Oct 5;355(14):1502-3; author reply 1503 [17021330.001]
  • [Cites] Clin Pharmacol Ther. 2000 Jun;67(6):621-30 [10872644.001]
  • (PMID = 17285128.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide; 0 / Sulfonamides; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC2360043
  •  go-up   go-down


13. Meşină C, Vasile I, Vîlcea ID, Paşalega M, Pârvănescu H, Calotă F, Georgescu CV, Ghiluşi M, Dumitrescu T, Mirea C, Mogoanţă S, Moraru E: [Soft tissue sarcoma--problems of diagnosis and treatment]. Chirurgia (Bucur); 2010 Mar-Apr;105(2):257-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue sarcoma--problems of diagnosis and treatment].
  • We present 3 cases of soft tissue sarcomas (the tumors were located to the right axilary region, perianal and dorsale face of the left leg) hospitalized in 2nd Surgical Clinic of Emergency Hospital of Craiova and we discuss the difficulties of diagnosis and treatment.
  • In conclusion surgical treatment is mainstay of treatment for soft-tissue sarcomas and is usefull the prompt diagnosis for decrease the risk of local recurrence and metastatic disease.
  • [MeSH-major] Sarcoma / diagnosis. Sarcoma / surgery
  • [MeSH-minor] Aged. Anal Canal / pathology. Anal Canal / surgery. Axilla / pathology. Axilla / surgery. Female. Humans. Leg / pathology. Leg / surgery. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20540243.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


1
Advertisement
4. Randall RL, Schabel KL, Hitchcock Y, Joyner DE, Albritton KH: Diagnosis and management of synovial sarcoma. Curr Treat Options Oncol; 2005 Nov;6(6):449-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of synovial sarcoma.
  • Synovial sarcoma is a unique tumor with substantial promise for biologically targeted therapy.
  • Research should be directed at understanding the fusion protein of the X,18 translocation and further validating the role of overexpressed proteins in synovial sarcoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Sarcoma, Synovial

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2001 Aug;31(4):362-72 [11433527.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):859-68 [8622034.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1238-47 [11230464.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3861-7 [12097301.001]
  • [Cites] Cancer. 2002 May 15;94(10):2712-8 [12173341.001]
  • [Cites] Orthopedics. 2004 Feb;27(2):209-12 [14992389.001]
  • [Cites] Mod Pathol. 2000 May;13(5):482-8 [10824918.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):265-74 [15337565.001]
  • [Cites] N Engl J Med. 1998 Jan 15;338(3):153-60 [9428816.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):83-8 [12694826.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):673-82 [9630174.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4040-50 [15364967.001]
  • [Cites] Oncogene. 2003 Oct 23;22(48):7628-31 [14576825.001]
  • [Cites] Radiother Oncol. 1996 Dec;41(3):209-14 [9027935.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):805-13 [10879732.001]
  • [Cites] Orthopedics. 1996 Aug;19(8):657-64 [8856775.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1809-14 [10468301.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1434-40 [12409719.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):259-65 [8407399.001]
  • [Cites] Hum Pathol. 2003 Jul;34(7):639-45 [12874758.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1596-606 [15050341.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):752-9 [15183478.001]
  • [Cites] Anal Cell Pathol. 1998;16(1):45-62 [9584899.001]
  • [Cites] Pathol Int. 1997 Dec;47(12):854-61 [9503467.001]
  • [Cites] Oncology. 1999;56(1):13-23 [9885372.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3794-803 [11078492.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):787-90 [1848542.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2087-94 [10811674.001]
  • [Cites] Oncogene. 2004 Jul 15;23(32):5551-7 [15077175.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1692-6 [9448617.001]
  • [Cites] J Transl Med. 2005 Jan 12;3(1):1 [15647119.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):127-31 [11316555.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):938-43 [14871970.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2491-502 [15503311.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):627-34 [15274077.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):830-8 [15641030.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] Hum Pathol. 1996 Oct;27(10):1060-5 [8892591.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):437-44 [15653701.001]
  • [Cites] Jpn J Clin Oncol. 1998 Feb;28(2):86-91 [9544821.001]
  • [Cites] Clin Orthop Relat Res. 2004 Feb;(419):155-61 [15021147.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1449-56 [14507652.001]
  • [Cites] Radiother Oncol. 1994 Oct;33(1):23-30 [7878206.001]
  • [Cites] J Immunol. 2002 Aug 1;169(3):1611-8 [12133991.001]
  • [Cites] Histol Histopathol. 2005 Jan;20(1):83-9 [15578426.001]
  • [Cites] J Am Coll Surg. 2001 Mar;192(3):305-13 [11245372.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1587-95 [12414507.001]
  • [Cites] Cancer Control. 2005 Jan-Feb;12(1):27-35 [15668650.001]
  • [Cites] Am J Clin Oncol. 2004 Apr;27(2):122-7 [15057149.001]
  • [Cites] Cancer Treat Res. 2004;120:151-67 [15217223.001]
  • [Cites] Histopathology. 2002 May;40(5):464-71 [12010367.001]
  • [Cites] Cancer Treat Rep. 1984 Sep;68(9):1067-78 [6383604.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3843-8 [11274403.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Nov;128(11):610-6 [12458341.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3375-80 [15310783.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):977-83 [10702413.001]
  • [Cites] Diagn Mol Pathol. 2000 Mar;9(1):1-8 [10718206.001]
  • [Cites] Arkh Patol. 2002 May-Jun;64(3):39-47 [15338724.001]
  • [Cites] J Clin Oncol. 1988 Sep;6(9):1491-500 [3047339.001]
  • (PMID = 16242050.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; 0 / SYT-SSX fusion protein; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 64
  •  go-up   go-down


15. Butler LM, Neilands TB, Mosam A, Mzolo S, Martin JN: A population-based study of how children are exposed to saliva in KwaZulu-Natal Province, South Africa: implications for the spread of saliva-borne pathogens to children. Trop Med Int Health; 2010 Apr;15(4):442-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: In sub-Saharan Africa, many viral infections, including Epstein-Barr virus, cytomegalovirus, Kaposi's sarcoma-associated herpesvirus and hepatitis B are acquired in childhood.
  • RESULTS: We identified 12 caregiving practices that expose a child's oral-respiratory mucosa, cutaneous surfaces or anal-rectal mucosa to saliva.

  • MedlinePlus Health Information. consumer health - Child Care.
  • MedlinePlus Health Information. consumer health - Viral Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):54-9 [10585583.001]
  • [Cites] Pediatrics. 2009 Aug;124(2):658-66 [19620190.001]
  • [Cites] J Med Virol. 2000 Aug;61(4):433-8 [10897060.001]
  • [Cites] Lancet. 2000 Sep 23;356(9235):1062-5 [11009141.001]
  • [Cites] Parassitologia. 2002 Jun;44(1-2):123-9 [12404820.001]
  • [Cites] J Infect Dis. 2003 Jun 1;187(11):1780-5 [12751036.001]
  • [Cites] Br J Cancer. 2003 Nov 17;89(10):2016-7 [14612917.001]
  • [Cites] J Infect Dis. 2004 Sep 15;190(6):1068-75 [15319855.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] Int J Cancer. 1978 Sep 15;22(3):239-43 [212369.001]
  • [Cites] Lancet. 1981 Nov 21;2(8256):1129-33 [6118576.001]
  • [Cites] Bull World Health Organ. 1981;59(4):605-10 [6274535.001]
  • [Cites] Lancet. 1983 May 28;1(8335):1203-6 [6133999.001]
  • [Cites] J Clin Pathol. 1991 May;44(5):366-9 [1646236.001]
  • [Cites] Epidemiol Rev. 1991;13:42-59 [1765119.001]
  • [Cites] J Pediatr. 1992 Apr;120(4 Pt 1):563-4 [1552394.001]
  • [Cites] New Microbiol. 1993 Jan;16(1):83-5 [8385733.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Am J Epidemiol. 1998 Mar 1;147(5):478-87 [9525535.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):817-20 [9714046.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):189-92 [10188717.001]
  • [Cites] Lancet Infect Dis. 2004 Dec;4(12):725-38 [15567122.001]
  • [Cites] J Infect Dis. 2006 Feb 1;193(3):422-6 [16388490.001]
  • [Cites] Trop Med Int Health. 2007 Jan;12(1):150-5 [17207159.001]
  • [Cites] PLoS Med. 2007 Dec;4(12):e334 [18052600.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):162-7 [19131893.001]
  • [Cites] J Infect Dis. 2009 Aug 1;200(3):430-8 [19534596.001]
  • [Cites] Int J STD AIDS. 2009 Aug;20(8):553-6 [19625587.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • (PMID = 20149165.001).
  • [ISSN] 1365-3156
  • [Journal-full-title] Tropical medicine & international health : TM & IH
  • [ISO-abbreviation] Trop. Med. Int. Health
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K01 HD052020
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS582774; NLM/ PMC4104610
  •  go-up   go-down


16. Dalton AK, Ako-Adjei D, Murray PS, Murray D, Vogt VM: Electrostatic interactions drive membrane association of the human immunodeficiency virus type 1 Gag MA domain. J Virol; 2007 Jun;81(12):6434-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myristoylation increases the barely detectable intrinsic affinity of the apo-protein for liposomes by only 10-fold, and the resulting affinity is still weak, similar to that of the naturally nonmyristoylated MA of Rous sarcoma virus.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MYRISTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2003 Apr;77(8):4805-17 [12663787.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):27923-9 [12761222.001]
  • [Cites] J Cell Biol. 2003 Aug 4;162(3):443-55 [12885763.001]
  • [Cites] Traffic. 2003 Nov;4(11):785-801 [14617360.001]
  • [Cites] J Virol. 2004 Jan;78(1):52-60 [14671087.001]
  • [Cites] J Virol. 2004 Feb;78(3):1552-63 [14722309.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):517-22 [14699046.001]
  • [Cites] J Mol Biol. 1998 Mar 27;277(2):161-9 [9514761.001]
  • [Cites] J Virol. 1998 Apr;72(4):2723-32 [9525590.001]
  • [Cites] EMBO J. 1998 May 1;17(9):2699-708 [9564051.001]
  • [Cites] Biophys J. 1998 Aug;75(2):769-76 [9675178.001]
  • [Cites] J Virol. 1998 Sep;72(9):7659-63 [9696871.001]
  • [Cites] Protein Eng. 1998 Sep;11(9):739-47 [9796821.001]
  • [Cites] J Virol. 1999 Mar;73(3):1902-8 [9971769.001]
  • [Cites] J Virol. 1999 Apr;73(4):2604-12 [10074105.001]
  • [Cites] J Virol. 1999 May;73(5):4136-44 [10196310.001]
  • [Cites] J Virol. 1999 Oct;73(10):8527-40 [10482606.001]
  • [Cites] Cell. 2005 Mar 11;120(5):663-74 [15766529.001]
  • [Cites] J Virol. 2005 May;79(10):6227-38 [15858007.001]
  • [Cites] Structure. 2005 Oct;13(10):1521-31 [16216583.001]
  • [Cites] Virology. 2005 Nov 25;342(2):190-200 [16139856.001]
  • [Cites] Biophys Chem. 2006 Jan 1;119(1):23-32 [16183191.001]
  • [Cites] Biochemistry. 2006 Apr 4;45(13):4077-83 [16566581.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11364-9 [16840558.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1761(8):812-26 [16928468.001]
  • [Cites] J Mol Biol. 2007 Jan 19;365(3):799-811 [17098251.001]
  • [Cites] PLoS Biol. 2006 Dec;4(12):e435 [17147474.001]
  • [Cites] Virology. 1980 Apr 15;102(1):205-10 [6245502.001]
  • [Cites] J Biol Chem. 1980 Oct 10;255(19):9044-50 [6251073.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Aug;86(15):5781-5 [2788277.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(2):523-7 [2405382.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5181-5 [8389472.001]
  • [Cites] Biochemistry. 1993 Oct 5;32(39):10436-43 [8399188.001]
  • [Cites] J Virol. 1993 Nov;67(11):6387-94 [8411340.001]
  • [Cites] J Virol. 1994 Apr;68(4):2556-69 [8139035.001]
  • [Cites] J Virol. 1994 May;68(5):3232-42 [8151785.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4594-8 [8183954.001]
  • [Cites] J Virol. 1994 Aug;68(8):5311-20 [8035531.001]
  • [Cites] J Virol. 1994 Oct;68(10):6644-54 [7521919.001]
  • [Cites] Biochemistry. 1994 Nov 8;33(44):13093-101 [7947714.001]
  • [Cites] Science. 1995 May 26;268(5214):1144-9 [7761829.001]
  • [Cites] Trends Biochem Sci. 1995 Jul;20(7):272-6 [7667880.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3099-104 [8610175.001]
  • [Cites] Biochemistry. 1996 Apr 2;35(13):3933-43 [8672424.001]
  • [Cites] Biophys J. 1996 Aug;71(2):561-75 [8842196.001]
  • [Cites] J Virol. 1996 Dec;70(12):8540-8 [8970978.001]
  • [Cites] J Virol. 1997 Sep;71(9):6582-92 [9261380.001]
  • [Cites] Biophys J. 1997 Oct;73(4):1717-27 [9336168.001]
  • [Cites] Science. 1997 Oct 31;278(5339):849-53 [9346481.001]
  • [Cites] J Mol Biol. 2007 Feb 16;366(2):574-85 [17188710.001]
  • [Cites] PLoS Pathog. 2007 Mar;3(3):e36 [17381240.001]
  • [Cites] Biochemistry. 1998 Feb 24;37(8):2145-59 [9485361.001]
  • [Cites] J Virol. 2000 Mar;74(6):2855-66 [10684302.001]
  • [Cites] J Virol. 2000 Apr;74(7):3264-72 [10708443.001]
  • [Cites] J Virol. 2000 Jun;74(11):5142-50 [10799589.001]
  • [Cites] J Virol. 2000 Jul;74(13):5845-55 [10846064.001]
  • [Cites] J Virol. 2000 Sep;74(18):8670-9 [10954568.001]
  • [Cites] J Virol. 2001 Sep;75(17):7913-24 [11483736.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10875-9 [11526217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13925-30 [11717449.001]
  • [Cites] Traffic. 2002 Oct;3(10):718-29 [12230470.001]
  • [Cites] J Virol. 2002 Nov;76(22):11177-85 [12388677.001]
  • [Cites] J Virol. 2003 Feb;77(3):1916-26 [12525626.001]
  • [Cites] Nat Struct Mol Biol. 2004 Jul;11(7):672-5 [15208690.001]
  • [Cites] J Virol. 2004 Sep;78(17):9560-3 [15308748.001]
  • [Cites] J Mol Biol. 2004 Oct 29;343(4):903-16 [15476809.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14889-94 [15465916.001]
  • [Cites] Virology. 1971 Oct;46(1):106-16 [4108030.001]
  • [Cites] Anal Biochem. 1972 Jun;47(2):614-9 [4338619.001]
  • [Cites] Virology. 1972 Nov;50(2):550-7 [4344196.001]
  • [Cites] J Virol. 2003 Apr;77(7):3973-84 [12634357.001]
  • (PMID = 17392361.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM066147; United States / NCI NIH HHS / CA / CA20087; United States / NIGMS NIH HHS / GM / GM66147; United States / NIAID NIH HHS / AI / AI54167; United States / NCI NIH HHS / CA / CA20087-S1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Gene Products, gag; 0 / Phospholipids; 0I3V7S25AW / Myristic Acid
  • [Other-IDs] NLM/ PMC1900125
  •  go-up   go-down


17. Aldo S, Salmaso L, El Barmi H, Pesarin F: Conditional tests in a competing risks model. Lifetime Data Anal; 2008 Jun;14(2):154-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Computer Simulation. Lymphoma, T-Cell / mortality. Male. Mice. Sarcoma / mortality

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lifetime Data Anal. 2002 Sep;8(3):277-88 [12182123.001]
  • [Cites] Lifetime Data Anal. 2002 Dec;8(4):401-12 [12471948.001]
  • [Cites] Biometrics. 1972 Jun;28(2):475-88 [4556703.001]
  • (PMID = 17943442.001).
  • [ISSN] 1380-7870
  • [Journal-full-title] Lifetime data analysis
  • [ISO-abbreviation] Lifetime Data Anal
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Dalton AK, Murray PS, Murray D, Vogt VM: Biochemical characterization of rous sarcoma virus MA protein interaction with membranes. J Virol; 2005 May;79(10):6227-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemical characterization of rous sarcoma virus MA protein interaction with membranes.
  • We have used an in vitro flotation assay to directly measure Rous sarcoma virus (RSV) MA-membrane interaction in the absence of host cell factors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1996 Apr;70(4):2664-8 [8642704.001]
  • [Cites] Biochemistry. 1996 Apr 2;35(13):3933-43 [8672424.001]
  • [Cites] Biophys J. 1996 Aug;71(2):561-75 [8842196.001]
  • [Cites] J Virol. 1996 Dec;70(12):8540-8 [8970978.001]
  • [Cites] Virology. 1972 Nov;50(2):550-7 [4344196.001]
  • [Cites] J Mol Biol. 1979 Jul 15;131(4):819-37 [229234.001]
  • [Cites] J Biol Chem. 1980 Oct 10;255(19):9044-50 [6251073.001]
  • [Cites] Biochim Biophys Acta. 1982 Jul 28;689(2):393-402 [6288099.001]
  • [Cites] Protein Eng. 1998 Sep;11(9):739-47 [9796821.001]
  • [Cites] Cell. 1998 Dec 11;95(6):847-58 [9865702.001]
  • [Cites] J Virol. 1999 Mar;73(3):1902-8 [9971769.001]
  • [Cites] J Virol. 1999 Apr;73(4):2604-12 [10074105.001]
  • [Cites] J Virol. 1999 May;73(5):4136-44 [10196310.001]
  • [Cites] Biochemistry. 1999 Jun 22;38(25):8056-63 [10387050.001]
  • [Cites] J Virol. 1999 Aug;73(8):7050-5 [10400808.001]
  • [Cites] Biophys J. 1999 Dec;77(6):3176-88 [10585939.001]
  • [Cites] Virology. 2000 Feb 15;267(2):289-98 [10662624.001]
  • [Cites] J Mol Biol. 2000 Feb 25;296(3):887-98 [10677289.001]
  • [Cites] J Virol. 2000 Mar;74(6):2855-66 [10684302.001]
  • [Cites] J Virol. 2000 Apr;74(7):3264-72 [10708443.001]
  • [Cites] J Virol. 2000 Jun;74(11):5142-50 [10799589.001]
  • [Cites] J Virol. 1997 May;71(5):3474-83 [9094619.001]
  • [Cites] J Virol. 1997 Jun;71(6):4425-35 [9151833.001]
  • [Cites] J Virol. 1997 Sep;71(9):6582-92 [9261380.001]
  • [Cites] Structure. 1997 Aug 15;5(8):985-9 [9309215.001]
  • [Cites] Biophys J. 1997 Oct;73(4):1717-27 [9336168.001]
  • [Cites] Science. 1997 Oct 31;278(5339):849-53 [9346481.001]
  • [Cites] Pac Symp Biocomput. 1996;:53-72 [9390223.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2580-5 [9482929.001]
  • [Cites] Biochemistry. 1998 Feb 24;37(8):2145-59 [9485361.001]
  • [Cites] J Mol Biol. 1998 Mar 27;277(2):161-9 [9514761.001]
  • [Cites] J Virol. 1998 Apr;72(4):2723-32 [9525590.001]
  • [Cites] EMBO J. 1998 May 1;17(9):2699-708 [9564051.001]
  • [Cites] J Mol Biol. 1998 Jun 19;279(4):921-8 [9642071.001]
  • [Cites] Biophys J. 1998 Aug;75(2):769-76 [9675178.001]
  • [Cites] J Virol. 1998 Sep;72(9):7659-63 [9696871.001]
  • [Cites] J Virol. 2003 Apr;77(8):4805-17 [12663787.001]
  • [Cites] Traffic. 2003 Apr;4(4):201-13 [12694559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5795-800 [12721375.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):27923-9 [12761222.001]
  • [Cites] J Cell Biol. 2003 Sep 29;162(7):1233-44 [14517204.001]
  • [Cites] Proteins. 2003;53 Suppl 6:430-5 [14579332.001]
  • [Cites] Traffic. 2003 Nov;4(11):785-801 [14617360.001]
  • [Cites] Traffic. 2003 Dec;4(12):902-10 [14617353.001]
  • [Cites] Cell. 2003 Nov 14;115(4):377-88 [14622593.001]
  • [Cites] J Mol Biol. 2004 Jan 2;335(1):275-82 [14659756.001]
  • [Cites] J Virol. 2004 Feb;78(3):1552-63 [14722309.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):517-22 [14699046.001]
  • [Cites] Physiol Rev. 2004 Jul;84(3):699-730 [15269334.001]
  • [Cites] J Virol. 2004 Sep;78(17):9560-3 [15308748.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14889-94 [15465916.001]
  • [Cites] Virology. 1971 Oct;46(1):106-16 [4108030.001]
  • [Cites] Anal Biochem. 1972 Jun;47(2):614-9 [4338619.001]
  • [Cites] J Mol Biol. 2000 May 19;298(5):841-57 [10801353.001]
  • [Cites] J Mol Biol. 2000 Jun 2;299(2):499-520 [10860755.001]
  • [Cites] J Mol Biol. 2000 Jun 30;300(1):103-12 [10864502.001]
  • [Cites] Bioinformatics. 2000 Apr;16(4):404-5 [10869041.001]
  • [Cites] J Mol Biol. 2000 Aug 4;301(1):173-90 [10926500.001]
  • [Cites] J Virol. 2000 Dec;74(23):11222-9 [11070020.001]
  • [Cites] J Virol. 2001 Mar;75(6):2753-64 [11222698.001]
  • [Cites] Virus Res. 2001 Jul;76(1):103-13 [11376850.001]
  • [Cites] J Mol Biol. 2001 Jun 29;310(1):243-57 [11419950.001]
  • [Cites] J Virol. 2001 Sep;75(17):7913-24 [11483736.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10875-9 [11526217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13925-30 [11717449.001]
  • [Cites] J Virol. 2002 Feb;76(4):1876-83 [11799182.001]
  • [Cites] Mol Cell. 2002 Jan;9(1):145-54 [11804593.001]
  • [Cites] Proteins. 2002 May 1;47(2):228-35 [11933069.001]
  • [Cites] J Clin Invest. 2002 Sep;110(5):597-603 [12208858.001]
  • [Cites] Structure. 2002 Dec;10(12):1627-36 [12467570.001]
  • [Cites] J Virol. 2003 Mar;77(5):3058-66 [12584331.001]
  • [Cites] Methods Biochem Anal. 2003;44:427-40 [12647398.001]
  • [Cites] J Virol. 1984 Oct;52(1):145-53 [6090691.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(2):523-7 [2405382.001]
  • [Cites] AIDS. 1991 Jun;5(6):639-54 [1883539.001]
  • [Cites] Proteins. 1991;11(4):281-96 [1758883.001]
  • [Cites] Biochemistry. 1992 Feb 18;31(6):1767-73 [1737030.001]
  • [Cites] Nature. 1992 Mar 5;356(6364):83-5 [1538787.001]
  • [Cites] Proteins. 1992 Apr;13(2):112-9 [1620693.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5181-5 [8389472.001]
  • [Cites] J Virol. 1993 Sep;67(9):5550-61 [8394460.001]
  • [Cites] Biochemistry. 1993 Oct 5;32(39):10436-43 [8399188.001]
  • [Cites] J Virol. 1993 Nov;67(11):6387-94 [8411340.001]
  • [Cites] J Virol. 1993 Nov;67(11):6487-98 [8411352.001]
  • [Cites] J Virol. 1994 Apr;68(4):2556-69 [8139035.001]
  • [Cites] J Virol. 1994 May;68(5):3232-42 [8151785.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4594-8 [8183954.001]
  • [Cites] J Virol. 1994 Aug;68(8):5311-20 [8035531.001]
  • [Cites] J Virol. 1994 Oct;68(10):6644-54 [7521919.001]
  • [Cites] Biochemistry. 1994 Nov 8;33(44):13093-101 [7947714.001]
  • [Cites] J Mol Biol. 1994 Nov 25;244(2):198-223 [7966331.001]
  • [Cites] Virology. 1994 Nov 15;205(1):336-44 [7975229.001]
  • [Cites] Science. 1995 May 26;268(5214):1144-9 [7761829.001]
  • [Cites] Trends Biochem Sci. 1995 Jul;20(7):272-6 [7667880.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3099-104 [8610175.001]
  • [Cites] J Virol. 1996 Apr;70(4):2269-76 [8642653.001]
  • (PMID = 15858007.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA020081; United States / NIAID NIH HHS / AI / AI54167
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 0 / MA protein, Rous sarcoma virus; 0 / Phosphoproteins; 0 / Viral Matrix Proteins
  • [Other-IDs] NLM/ PMC1091718
  •  go-up   go-down


19. Malone VS, Dobin SM, Jones KA, Donner LR: CD99-positive large cell neuroendocrine carcinoma with rearranged EWSR1 gene in an infant: a case of prognostically favorable tumor. Virchows Arch; 2010 Sep;457(3):389-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor arose at the anal verge of a 1-year-old girl.
  • The diagnosis of this CD99-positive tumor was supported by expression of epithelial (keratins, EMA, and Ep-CAM) and neuroendocrine (chromogranin A, synaptophysin, and neuron-specific enolase) markers and absence of immunoreactivity for Fli-1.
  • Because the tumor was initially misclassified as an extraskeletal Ewing's sarcoma, the patient was treated according to the Ewing's sarcoma treatment protocol.
  • She remains free of tumor 8 years after initial diagnosis.
  • [MeSH-major] Antigens, CD / biosynthesis. Anus Neoplasms / pathology. Calmodulin-Binding Proteins / genetics. Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / pathology. Cell Adhesion Molecules / biosynthesis. RNA-Binding Proteins / genetics
  • [MeSH-minor] Antigens, CD99. Biomarkers, Tumor / analysis. Bone Neoplasms / pathology. Diagnostic Errors. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Sarcoma, Ewing / pathology

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroendocrinology. 2004;80(6):394-424 [15838182.001]
  • [Cites] Histopathology. 1992 May;20(5):437-9 [1587495.001]
  • [Cites] J Child Neurol. 2001 Aug;16(8):548-52 [11510923.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Dec;48(12):1051-6 [19760602.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Oct;194(1):53-7 [19737655.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1025-33 [16006796.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):265-7 [16082253.001]
  • [Cites] Am J Surg. 1995 Dec;170(6):606-8 [7492010.001]
  • [Cites] J Pediatr Surg. 2000 Sep;35(9):1282-6 [10999679.001]
  • [Cites] Curr Top Pathol. 1995;89:31-45 [7882716.001]
  • [Cites] Virchows Arch. 2010 Feb;456(2):219-34 [19936782.001]
  • [Cites] Virchows Arch. 1998 Jul;433(1):35-40 [9692823.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1742-8 [18769338.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12 ):1588-94 [17122516.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2259-68 [19318479.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Nov;195(1):12-8 [19837262.001]
  • [Cites] Neuroendocrinology. 2008;87(1):40-6 [17940332.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):43-50 [15735854.001]
  • [Cites] J Pathol. 2008 May;215(1):78-86 [18338330.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):163-9 [15043285.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):410-6 [10716155.001]
  • [Cites] Histopathology. 2007 Jan;50(1):163-74 [17204029.001]
  • [Cites] Pediatr Blood Cancer. 2008 Mar;50(3):588-93 [17405155.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jul;47(7):558-64 [18383210.001]
  • [Cites] Int J Surg Pathol. 2000 Jan;8(1):59-65 [11493965.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):227-32 [1712661.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12 ):1657-62 [11117787.001]
  • [Cites] Adv Anat Pathol. 2009 Nov;16(6):383-91 [19851129.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Jul;16(4):344-8 [18528283.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Nov;123(1):1-26 [11120329.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):273-4 [11176079.001]
  • [Cites] Arch Pathol Lab Med. 2003 Sep;127(9):1200-3 [12946222.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4568-76 [12907633.001]
  • [Cites] Oncogene. 2000 Aug 3;19(33):3799-804 [10949935.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):194-203 [10968705.001]
  • [Cites] J Pediatr Surg. 1990 Oct;25(10):1073-5 [2262861.001]
  • [Cites] Virchows Arch. 2000 Sep;437(3):270-4 [11037347.001]
  • (PMID = 20617339.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD99; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Calmodulin-Binding Proteins; 0 / Cell Adhesion Molecules; 0 / EWSR1 protein, human; 0 / RNA-Binding Proteins
  •  go-up   go-down


20. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, Ries LA, Fraumeni JF Jr: Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol; 2010 Nov 20;28(33):4935-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90).

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):159-66 [15970927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):419-20 [16125820.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):108-15 [16708354.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1481-8 [17043014.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2314-20 [17107903.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):135-42 [17235495.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):151-6 [17351903.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4617-26 [17311989.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):43-50 [17906957.001]
  • [Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1850-7 [18347006.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15 [18402527.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1481-94 [18518779.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1175-83 [18971419.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):874-80 [11241258.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1610-8 [11250989.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3878-84 [12228208.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]
  • [Cites] Med Oncol. 2003;20(3):211-20 [14514970.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):383-9 [14746857.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1222-8 [14576060.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1083-91 [15247562.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):565-71 [8636772.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):216-28 [15578683.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4573-5 [15741224.001]
  • (PMID = 20940199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3020697
  •  go-up   go-down


21. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort: Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol; 2009 Dec;10(12):1152-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We investigated the incidence of both AIDS-defining cancers (Kaposi's sarcoma, non-Hodgkin lymphoma, and cervical cancer) and non-AIDS-defining cancers (Hodgkin's lymphoma, lung cancer, liver cancer, and anal cancer) in 52 278 patients followed up in the French Hospital Database on HIV cohort during 1998-2006 (median follow-up 4.9 years, IQR 2.1-7.9; 255 353 person-years).
  • FINDINGS: Current CD4 cell count was the most predictive risk factor for all malignancies apart from anal cancer.
  • Compared with patients with CD4 count greater than 500 cells per microL, rate ratios (RR) ranged from 1.9 (95% CI 1.3-2.7) for CD4 counts 350-499 cells per microL to 25.2 (17.1-37.0) for counts less than 50 cells per microL for Kaposi's sarcoma (p<0.0001), from 1.3 (0.9-2.0) to 14.8 (9.7-22.6) for non-Hodgkin lymphoma (p<0.0001), from 1.2 (0.7-2.2) to 5.4 (2.4-12.1) for Hodgkin's lymphoma (p<0.0001), from 2.2 (1.3-3.6) to 8.5 (4.3-16.7) for lung cancer (p<0.0001), and from 2.0 (0.9-4.5) to 7.6 (2.7-20.8) for liver cancer (p<0.0001).
  • The risk of Kaposi's sarcoma and non-Hodgkin lymphoma increased for current plasma HIV RNA greater than 100 000 copies per mL compared with patients with controlled viral load (RR 3.1, 95% CI 2.3-4.2, p<0.0001; and 2.9, 2.1-3.9, p<0.0001, respectively), whereas cART was independently associated with a decreased incidence (0.3, 0.2-0.4, p<0.0001; and 0.8, 0.6-1.0, p=0.07, respectively).
  • The risk of anal cancer increased with the time during which the CD4 count was less than 200 cells per microL (1.3 per year, 1.2-1.5; p=0.0001), and viral load was greater than 100 000 copies per mL (1.2 per year, 1.1-1.4, p=0.005).
  • INTERPRETATION: cART would be most beneficial if it restores or maintains CD4 count above 500 cells per microL, thereby indicating an earlier diagnosis of HIV infection and an earlier treatment initiation.


22. Rajwanshi A, Srinivas R, Upasana G: Malignant small round cell tumors. J Cytol; 2009 Jan;26(1):1-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They generally include Ewing's sarcoma, peripheral neuroectodermal tumor, rhabdomyosarcoma, synovial sarcoma, non-Hodgkin's lymphoma, retinoblastoma, neuroblastoma, hepatoblastoma, and nephroblastoma or Wilms' tumor.
  • Other differential diagnoses of small round cell tumors include small cell osteogenic sarcoma, undifferentiated hepatoblastoma, granulocytic sarcoma, and intraabdominal desmoplastic small round cell tumor.
  • Differential diagnosis of small round cell tumors is particularly difficult due to their undifferentiated or primitive character.
  • Tumors that show good differentiation are generally easy to diagnose, but when a tumor is poorly differentiated, identification of the diagnostic, morphological features is difficult and therefore, no definitive diagnosis may be possible.
  • As seen in several study reports, fine needle aspiration cytology (FNAC) has become an important modality of diagnosis for these tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1992 Feb 15;69(4):1067-73 [1370916.001]
  • [Cites] Cancer Res. 1992 Sep 1;52(17):4701-5 [1380888.001]
  • [Cites] Diagn Cytopathol. 1992;8(5):465-74 [1396025.001]
  • [Cites] Diagn Cytopathol. 2003 Dec;29(6):341-3 [14648792.001]
  • [Cites] Diagn Cytopathol. 2004 Jan;30(1):19-23 [14696140.001]
  • [Cites] Neuroscience. 1992 Aug;49(3):497-528 [1501763.001]
  • [Cites] Diagn Cytopathol. 2004 Sep;31(3):147-54 [15349982.001]
  • [Cites] Diagn Cytopathol. 2004 Sep;31(3):159-63 [15349984.001]
  • [Cites] Diagn Cytopathol. 2005 May;32(5):281-6 [15830360.001]
  • [Cites] J Histochem Cytochem. 2005 Dec;53(12):1433-40 [15956022.001]
  • [Cites] Indian J Pathol Microbiol. 2004 Jul;47(3):309-18 [16295413.001]
  • [Cites] Eur J Cancer. 1991;27(6):762-5 [1676900.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):962-8 [16861966.001]
  • [Cites] Acta Cytol. 1990 Jan-Feb;34(1):79-83 [1688679.001]
  • [Cites] Cytojournal. 2006;3:24 [17069647.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):499-513 [1709557.001]
  • [Cites] Cancer. 2007 Feb 25;111(1):41-6 [17173322.001]
  • [Cites] Br J Cancer. 1991 Dec;64(6):1039-42 [1764365.001]
  • [Cites] Hum Mol Genet. 1997 Sep;6(9):1549-58 [9285793.001]
  • [Cites] Pathol Int. 1997 Sep;47(9):637-41 [9311017.001]
  • [Cites] N Engl J Med. 1998 Jan 15;338(3):153-60 [9428816.001]
  • [Cites] Am J Clin Pathol. 1998 May;109(5):625-30 [9576583.001]
  • [Cites] J Korean Med Sci. 1998 Aug;13(4):395-9 [9741544.001]
  • [Cites] Diagn Cytopathol. 1998 Nov;19(5):382-4 [9812236.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2801-5 [9829745.001]
  • [Cites] Nature. 1978 Dec 21-28;276(5690):834-6 [31568.001]
  • [Cites] Acta Cytol. 1988 May-Jun;32(3):367-76 [3287819.001]
  • [Cites] Acta Cytol. 1988 Jan-Feb;32(1):1-10 [3336946.001]
  • [Cites] Am J Pathol. 1986 Mar;122(3):433-42 [3513600.001]
  • [Cites] Cancer. 1986 Feb 15;57(4):797-803 [3943013.001]
  • [Cites] Cancer. 1985 Sep 15;56(6):1490-2 [4027884.001]
  • [Cites] Am J Pathol. 1995 Dec;147(6):1584-91 [7495283.001]
  • [Cites] Am J Pathol. 1995 Dec;147(6):1799-810 [7495304.001]
  • [Cites] EMBO J. 1995 May 15;14(10):2333-40 [7539744.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):659-65 [7755152.001]
  • [Cites] J Pathol. 1995 Apr;175(4):391-6 [7790992.001]
  • [Cites] Ann Clin Lab Sci. 1994 Jan-Feb;24(1):6-11 [8147568.001]
  • [Cites] Pathol Res Pract. 1993 Dec;189(10):111-36 [8183732.001]
  • [Cites] Acta Cytol. 1994 May-Jun;38(3):355-60 [8191824.001]
  • [Cites] Am J Pathol. 1994 Jun;144(6):1121-34 [8203453.001]
  • [Cites] Am J Surg Pathol. 1993 Jan;17(1):1-13 [8383465.001]
  • [Cites] Histopathology. 1993 Jul;23(1):93-7 [8396065.001]
  • [Cites] Diagn Cytopathol. 1995 Nov;13(4):310-5 [8599914.001]
  • [Cites] Int J Gynecol Pathol. 1995 Jul;14(3):260-5 [8600079.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1214-9 [8635146.001]
  • [Cites] J Pediatr Hematol Oncol. 1996 Aug;18(3):293-8 [8689345.001]
  • [Cites] Acta Cytol. 1997 Jul-Aug;41(4):1035-47 [9250296.001]
  • [Cites] Arch Pathol Lab Med. 1999 Mar;123(3):206-12 [10086508.001]
  • [Cites] Histopathology. 1999 Mar;34(3):205-10 [10217560.001]
  • [Cites] Diagn Cytopathol. 1999 May;20(5):271-7 [10319227.001]
  • [Cites] Diagn Cytopathol. 1999 May;20(5):278-84 [10319228.001]
  • [Cites] Am J Pathol. 1999 Jul;155(1):17-21 [10393831.001]
  • [Cites] Diagn Cytopathol. 1999 Aug;21(2):81-91 [10425044.001]
  • [Cites] Hum Pathol. 2000 Feb;31(2):246-50 [10685642.001]
  • [Cites] Diagn Cytopathol. 2000 Aug;23(2):118-23 [10888758.001]
  • [Cites] Acta Cytol. 2000 Jul-Aug;44(4):524-32 [10934943.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):776-81 [11395555.001]
  • [Cites] Biol Pharm Bull. 2004 Mar;27(3):315-8 [14993794.001]
  • [Cites] Cytometry B Clin Cytom. 2005 Mar;64(1):34-42 [15669024.001]
  • [Cites] Diagn Cytopathol. 2005 Apr;32(4):211-6 [15754373.001]
  • [Cites] Diagn Cytopathol. 2005 Jun;32(6):330-5 [15880716.001]
  • [Cites] Cytopathology. 2007 Aug;18(4):234-40 [17559565.001]
  • [Cites] Diagn Mol Pathol. 1995 Sep;4(3):162-73 [7493135.001]
  • [Cites] Acta Cytol. 1993 Jul-Aug;37(4):477-82 [8392251.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):406-12 [8604806.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1886-93 [1848471.001]
  • [Cites] Am J Pathol. 1991 Aug;139(2):317-25 [1867320.001]
  • [Cites] Diagn Cytopathol. 1991;7(5):451-61 [1954821.001]
  • [Cites] Cell. 1990 Feb 9;60(3):509-20 [2154335.001]
  • [Cites] Am J Pathol. 1990 Dec;137(6):1283-91 [2260621.001]
  • [Cites] Hum Pathol. 1986 Oct;17(10):996-1008 [2428727.001]
  • [Cites] Diagn Cytopathol. 1989;5(4):378-82 [2612314.001]
  • [Cites] Cancer. 1985 Apr 15;55(8):1805-17 [2983864.001]
  • [Cites] Diagn Cytopathol. 1997 Jun;16(6):513-7 [9181317.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1807-12 [9846971.001]
  • [Cites] Diagn Cytopathol. 1998 Dec;19(6):410-6 [9839129.001]
  • [Cites] J Surg Oncol. 1999 Aug;71(4):269-72 [10440769.001]
  • [Cites] Mod Pathol. 2000 May;13(5):482-8 [10824918.001]
  • [Cites] Acta Cytol. 2000 May-Jun;44(3):332-6 [10833987.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1792-9 [11100059.001]
  • [Cites] Diagn Cytopathol. 2001 Apr;24(4):233-9 [11285617.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):255-60 [11556754.001]
  • [Cites] Anal Quant Cytol Histol. 2001 Dec;23(6):405-12 [11777275.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):135-40 [11782370.001]
  • [Cites] Cancer. 2002 Feb 25;96(1):21-31 [11836699.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):965-77 [12170083.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1175-83 [12218574.001]
  • [Cites] Diagn Cytopathol. 2003 May;28(5):232-8 [12722117.001]
  • [Cites] Acta Cytol. 1992 Jul-Aug;36(4):541-50 [1321999.001]
  • (PMID = 21938141.001).
  • [ISSN] 0970-9371
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3167982
  • [Keywords] NOTNLM ; Fine needle aspiration cytology / ancillary techniques / malignant small round cell tumors
  •  go-up   go-down


23. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D: AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol; 2008 Oct 10;26(29):4834-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the advent of cART has resulted in reductions in the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma, non-AIDS-defining malignancies present an increased risk for HIV-infected patients, characterized by some common clinical features, generally with a more aggressive behavior and a more advanced disease at diagnosis, which is responsible for poorer patient outcomes.
  • Specific therapeutic recommendations are lacking for these new nonopportunistic malignancies, such as Hodgkin's lymphoma, anal cancer, lung cancer, hepatocarcinoma, and many others.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


24. Bozzi F, Ferrari A, Negri T, Conca E, Luca da R, Losa M, Casieri P, Orsenigo M, Lampis A, Meazza C, Casanova M, Pierotti MA, Tamborini E, Pilotti S: Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation. Transl Oncol; 2008 Jul;1(2):95-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation.
  • Synovial sarcoma (SS) is the most frequent nonrhabdomyosarcomatous soft tissue sarcoma encountered in adolescents and young adults, and despite advances in the treatment of local disease, metastases remain the main cause of death.


25. Katona TM, Lopez-Beltran A, MacLennan GT, Cheng L, Montironi R, Cheng L: Soft tissue tumors of the penis: a review. Anal Quant Cytol Histol; 2006 Aug;28(4):193-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this review is to aid the practicing surgical pathologist in distinguishing penile soft tissue tumors, such as sarcomatoid squamous cell carcinoma, from other prognostically and therapeutically important entities in the differential diagnosis.
  • Among reported cases, the most frequent malignant penile soft tissue tumors are Kaposi sarcoma and leiomyosarcoma.
  • Accurate diagnosis is best facilitated by consideration of all available aspects of the case, including clinical information, histopathologic findings and immunohistochemical results.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16927639.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 63
  •  go-up   go-down


26. Ang D, Luman W, Ooi CJ: Early experience with double balloon enteroscopy: a leap forward for the gastroenterologist. Singapore Med J; 2007 Jan;48(1):50-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: DBE was carried out via the oral approach (19 patients), anal approach (eight patients), and both approaches (three patients).
  • A positive diagnosis was achieved in 19 patients: jejunal gastrointestinal stromal tumour (GIST) (one), jejunal sarcoma (one), jejunal adenocarcinoma (one), duodenal adenocarcinoma (one), malignant lymphangioma (one), eosinophilic enteritis (one), pseudomembranous ileitis (one), tuberculous ileitis (one), jejunitis/ileitis (seven), lymphangiectasia attributed to relapsed Non-Hodgkins lymphoma (one), combination of angiodysplastic lesions and apthous jejunal/ileal lesions (one), and focal villous atrophy (two).
  • [MeSH-major] Endoscopes, Gastrointestinal / standards. Endoscopy, Gastrointestinal / methods. Intestinal Diseases / diagnosis. Intestine, Small / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17245517.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


27. Chen W, Jarzyna PA, van Tilborg GA, Nguyen VA, Cormode DP, Klink A, Griffioen AW, Randolph GJ, Fisher EA, Mulder WJ, Fayad ZA: RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J; 2010 Jun;24(6):1689-99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe.
  • High density lipoprotein (HDL), an endogenous nanoparticle, transports fat throughout the body and is capable of transferring cholesterol from atheroma in the vessel wall to the liver.
  • In the present study, we utilized HDL as a multimodal nanoparticle platform for tumor targeting and imaging via nonspecific accumulation and specific binding to angiogenically activated blood vessels.
  • We reconstituted HDL (rHDL) with amphiphilic gadolinium chelates and fluorescent dyes.
  • To target angiogenic endothelial cells, rHDL was functionalized with alphavbeta3-integrin-specific RGD peptides (rHDL-RGD).
  • Nonspecific RAD peptides were conjugated to rHDL nanoparticles as a control (rHDL-RAD).
  • It was observed in vitro that all 3 nanoparticles were phagocytosed by macrophages, while alphavbeta3-integrin-specific rHDL-RGD nanoparticles were preferentially taken up by endothelial cells.
  • The uptake of nanoparticles in mouse tumors was evaluated in vivo using near infrared (NIR) and MR imaging.
  • All nanoparticles accumulated in tumors but with very different accumulation/binding kinetics as observed by NIR imaging.
  • Moreover, confocal microscopy revealed rHDL-RGD to be associated with tumor endothelial cells, while rHDL and rHDL-RAD nanoparticles were mainly found in the interstitial space.
  • This study demonstrates the ability to reroute HDL from its natural targets to tumor blood vessels and its potential for multimodal imaging of tumor-associated processes.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Magn Reson Med. 2009 May;61(5):1022-32 [19235908.001]
  • [Cites] Pathobiology. 2001;69(4):225-9 [12007282.001]
  • [Cites] Mol Imaging. 2002 Oct;1(4):365-77 [12940233.001]
  • [Cites] Technol Cancer Res Treat. 2003 Dec;2(6):553-62 [14640766.001]
  • [Cites] Nat Biotechnol. 2004 Jan;22(1):93-7 [14661026.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Atherosclerosis. 1994 Feb;105(2):145-57 [8003090.001]
  • [Cites] J Lipid Res. 1999 Sep;40(9):1647-54 [10484611.001]
  • [Cites] J Am Chem Soc. 2004 Dec 22;126(50):16316-7 [15600321.001]
  • [Cites] J Am Coll Cardiol. 2005 Sep 20;46(6):937-54 [16168274.001]
  • [Cites] Mol Imaging. 2005 Jul-Sep;4(3):143-64 [16194447.001]
  • [Cites] J Am Coll Cardiol. 2005 Oct 4;46(7):1209-18 [16198833.001]
  • [Cites] FASEB J. 2005 Dec;19(14):2008-10 [16204353.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17757-62 [16306263.001]
  • [Cites] Nano Lett. 2006 Jan;6(1):1-6 [16402777.001]
  • [Cites] Magn Reson Med. 2006 Mar;55(3):491-7 [16450336.001]
  • [Cites] Nat Clin Pract Cardiovasc Med. 2006 Mar;3(3):144-53 [16505860.001]
  • [Cites] Nano Lett. 2006 Oct;6(10):2220-4 [17034087.001]
  • [Cites] J Lipid Res. 2006 Nov;47(11):2408-21 [16926440.001]
  • [Cites] Am J Cardiol. 2006 Dec 1;98(11):1542-9 [17126667.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1951-7 [17278104.001]
  • [Cites] NMR Biomed. 2007 Apr;20(2):77-89 [16952123.001]
  • [Cites] Bioconjug Chem. 2007 Mar-Apr;18(2):379-88 [17298029.001]
  • [Cites] J Am Chem Soc. 2007 May 9;129(18):5798-9 [17428054.001]
  • [Cites] Curr Opin Lipidol. 2007 Aug;18(4):443-50 [17620862.001]
  • [Cites] Expert Opin Drug Deliv. 2007 Nov;4(6):665-75 [17970668.001]
  • [Cites] Int J Nanomedicine. 2007;2(4):767-74 [18203443.001]
  • [Cites] Nutr Metab Cardiovasc Dis. 2008 May;18(4):329-35 [18378129.001]
  • [Cites] Curr Opin Cardiol. 2008 Jul;23(4):370-8 [18520722.001]
  • [Cites] FASEB J. 2008 Aug;22(8):2758-67 [18362202.001]
  • [Cites] Small. 2008 Sep;4(9):1437-44 [18712752.001]
  • [Cites] Nano Lett. 2008 Nov;8(11):3715-23 [18939808.001]
  • [Cites] Neoplasia. 2008 Dec;10(12):1459-69 [19048124.001]
  • [Cites] Clin Sci (Lond). 2009 Jan;116(2):87-98 [19076062.001]
  • [Cites] Bioconjug Chem. 2008 Dec;19(12):2471-9 [19035793.001]
  • [Cites] Contrast Media Mol Imaging. 2008 Nov-Dec;3(6):233-42 [19072768.001]
  • [Cites] Angiogenesis. 2009;12(1):17-24 [19067197.001]
  • [Cites] Magn Reson Med. 2009 May;61(5):1049-58 [19215042.001]
  • [Cites] Bioconjug Chem. 2002 Jan-Feb;13(1):128-35 [11792188.001]
  • (PMID = 20075195.001).
  • [ISSN] 1530-6860
  • [Journal-full-title] FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • [ISO-abbreviation] FASEB J.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5R24 CA-095823-04; United States / PHS HHS / / R01 H-71021; United States / NIBIB NIH HHS / EB / EB-009638; United States / PHS HHS / / R01 H-78667; United States / NIBIB NIH HHS / EB / R01 EB009638; United States / NCI NIH HHS / CA / R24 CA095823; United States / NCRR NIH HHS / RR / 1 S10 RR-09145-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 0 / Lipoproteins, HDL; 0 / Molecular Probes; 0 / Oligopeptides; 99896-85-2 / arginyl-glycyl-aspartic acid
  • [Other-IDs] NLM/ PMC2874482
  •  go-up   go-down


28. Chatelain D, Mokrani N, Fléjou JF: [Anal and anal margin tumors]. Ann Pathol; 2007 Dec;27(6):459-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal and anal margin tumors].
  • Tumors of the anal canal and anal margin are rare.
  • [MeSH-major] Anus Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Endocrine Gland Neoplasms / epidemiology. Endocrine Gland Neoplasms / pathology. France / epidemiology. Humans. Incidence. Leiomyosarcoma / pathology. Lymphoma / pathology. Melanoma / epidemiology. Melanoma / pathology. Papilloma / pathology. Sarcoma, Kaposi / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18554556.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 110
  •  go-up   go-down


29. Rivero Fernández M, García Martos M, Sanz Moya P, Vázquez Romero M, Fernández Amago MT, García Benayas MT, Sánchez-Pobre Bejarano P: [Kaposi's sarcoma with colorectal and anal canal involvement]. Gastroenterol Hepatol; 2010 Aug-Sep;33(7):508-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Kaposi's sarcoma with colorectal and anal canal involvement].
  • [Transliterated title] Sarcoma de Kaposi con afectación colorrectal y del canal anal.
  • Kaposi's sarcoma (KS) is a low-grade vascular tumor, with four main variants, one of which is fairly prevalent in HIV-infected patients.
  • The gastrointestinal tract is involved in 40% of patients, but rectal and anal canal involvement is exceptional.
  • We report the case of a 39-year-old HIV-infected man with an unusual presentation of KS with colorectal and anal canal involvement in the absence of cutaneous disease.
  • [MeSH-major] Anus Neoplasms. Colorectal Neoplasms. Neoplasms, Multiple Primary. Sarcoma, Kaposi

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] .
  • (PMID = 20630624.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


30. Sápi Z, Pápai Z, Hruska A, Antal I, Bodó M, Orosz Z: Her-2 oncogene amplification, chromosome 17 and DNA ploidy status in synovial sarcoma. Pathol Oncol Res; 2005;11(3):133-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Her-2 oncogene amplification, chromosome 17 and DNA ploidy status in synovial sarcoma.
  • The treatment options for synovial sarcoma (SS) are very limited, though this type of sarcoma seems to be more heterogeneous than it has been traditionally considered.
  • [MeSH-major] Chromosomes, Human, Pair 17. DNA, Neoplasm / genetics. Genes, erbB-2. Sarcoma, Synovial / genetics

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2001 Aug;31(4):362-72 [11433527.001]
  • [Cites] Histopathology. 1994 Nov;25(5):455-61 [7868086.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Nov;49(5):629-37 [10197079.001]
  • [Cites] Hum Pathol. 2003 Jul;34(7):639-45 [12874758.001]
  • [Cites] Anal Cell Pathol. 2001;23(2):89-95 [11904464.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2596-607 [10375108.001]
  • [Cites] Br J Cancer. 1991 Apr;63(4):601-8 [1673627.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3794-803 [11078492.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2087-94 [10811674.001]
  • [Cites] Am J Clin Pathol. 1997 Oct;108(4):456-63 [9322600.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):830-8 [15641030.001]
  • [Cites] Mod Pathol. 2001 Dec;14(12):1277-83 [11743051.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1419-26 [8608524.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):437-44 [15653701.001]
  • [Cites] Cancer. 1990 May 15;65(10):2295-300 [2161280.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1587-95 [12414507.001]
  • [Cites] Anal Cell Pathol. 1994 Feb;6(2):165-80 [8167099.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Nov;128(11):610-6 [12458341.001]
  • (PMID = 16195766.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


31. Cook MB, Dawsey SM, Freedman ND, Inskip PD, Wichner SM, Quraishi SM, Devesa SS, McGlynn KA: Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev; 2009 Apr;18(4):1174-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The 10 cancers with the largest male-to-female IRR were Kaposi sarcoma (28.73), lip (7.16), larynx (5.17), mesothelioma (4.88), hypopharynx (4.13), urinary bladder (3.92), esophagus (3.49), tonsil (3.07), oropharynx (3.06), and other urinary organs (2.92).
  • Only 5 cancers had a higher incidence in females compared with males: breast (0.01), peritoneum, omentum, and mesentery (0.18), thyroid (0.39), gallbladder (0.57), and anus, anal canal, and anorectum (0.81).

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Res. 2007 May;104(1):128-34 [17084838.001]
  • [Cites] Environ Res. 2007 May;104(1):85-95 [16996054.001]
  • [Cites] Am J Epidemiol. 2007 Jun 15;165(12):1424-33 [17420181.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2557-76 [17570226.001]
  • [Cites] Verh K Acad Geneeskd Belg. 2007;69(3):105-30 [17580814.001]
  • [Cites] Science. 2007 Jul 6;317(5834):121-4 [17615358.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4365-70 [17671117.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2007 Nov 9;56(44):1157-61 [17989644.001]
  • [Cites] Cell Prolif. 2007 Dec;40(6):921-35 [18021179.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):352-8 [18268119.001]
  • [Cites] Adv Exp Med Biol. 2008;624:104-16 [18348451.001]
  • [Cites] Aging Clin Exp Res. 2008 Apr;20(2):91-102 [18431075.001]
  • [Cites] Br J Cancer. 2008 Nov 4;99(9):1506-10 [18841152.001]
  • [Cites] Eur J Cancer. 2008 Nov;44(16):2397-403 [18755583.001]
  • [Cites] Nat Rev Genet. 2008 Dec;9(12):911-22 [19002143.001]
  • [Cites] Eur J Endocrinol. 2008 Dec;159(6):659-73 [18713843.001]
  • [Cites] Soc Sci Med. 2000 May;50(10):1385-401 [10741575.001]
  • [Cites] Eur J Cancer Prev. 2000 Dec;9(6):433-7 [11201683.001]
  • [Cites] J Gend Specif Med. 2000 Mar-Apr;3(2):42-4 [11253245.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Feb;16(2):132-6 [11207891.001]
  • [Cites] J Womens Health Gend Based Med. 2001 Jun;10(5):433-9 [11445042.001]
  • [Cites] Indian J Cancer. 2000 Jun-Sep;37(2-3):114-22 [11876609.001]
  • [Cites] Tumori. 2002 Jan-Feb;88(1):13-7 [12004843.001]
  • [Cites] Thyroid. 2002 Oct;12(10):889-96 [12487771.001]
  • [Cites] J Gastroenterol. 2003 Mar;38 Suppl 15:3-6 [12698863.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1625-38 [12711737.001]
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):766-72 [14696105.001]
  • [Cites] Urol Clin North Am. 2004 May;31(2):237-47 [15123404.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Br J Cancer. 1969 Mar;23(1):26-30 [4181296.001]
  • [Cites] World Health Stat Q. 1978;31(4):360-83 [735114.001]
  • [Cites] Annu Rev Public Health. 1984;5:433-58 [6372818.001]
  • [Cites] Ann N Y Acad Sci. 1990;609:290-7; discussion 297-9 [2264652.001]
  • [Cites] World Health Stat Q. 1992;45(1):117-64 [1413853.001]
  • [Cites] Int J Epidemiol. 1995 Aug;24(4):720-9 [8550269.001]
  • [Cites] J Intern Med. 1997 Jan;241(1):71-9 [9042096.001]
  • [Cites] Acta Biotheor. 1998 Jun;46(2):157-60 [9691260.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1626-36 [9811312.001]
  • [Cites] Int J Cancer. 2005 Mar 10;114(1):101-8 [15523697.001]
  • [Cites] Am J Gastroenterol. 2005 Mar;100(3):560-7 [15743352.001]
  • [Cites] Hum Reprod Update. 2005 Jul-Aug;11(4):411-23 [15817524.001]
  • [Cites] Ann Epidemiol. 2005 Aug;15(7):545-50 [16029848.001]
  • [Cites] Br J Nutr. 2005 Aug;94(2):139-40 [16115345.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):859-61 [16189516.001]
  • [Cites] Am J Epidemiol. 2005 Dec 1;162(11):1050-61 [16221805.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):136-41 [16404367.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):369-80 [16527702.001]
  • [Cites] Ann Intern Med. 2006 May 16;144(10):705-14 [16702586.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):872-8 [16702363.001]
  • [Cites] Cancer Detect Prev. 2006;30(2):152-7 [16647226.001]
  • [Cites] Br J Cancer. 2006 Jul 3;95(1):87-90 [16721368.001]
  • [Cites] Clin Otolaryngol. 2006 Aug;31(4):259-66 [16911640.001]
  • [Cites] Mayo Clin Proc. 2007 Mar;82(3):364-80 [17352373.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • (PMID = 19293308.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010126-15
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS160092; NLM/ PMC2793271
  •  go-up   go-down


32. Abbott DE, Halverson AL, Wayne JD, Kim JY, Talamonti MS, Dumanian GA: The oblique rectus abdominal myocutaneous flap for complex pelvic wound reconstruction. Dis Colon Rectum; 2008 Aug;51(8):1237-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for flap reconstruction included abdominal perineal resection for anal/rectal cancer, pelvic sarcoma/sacral resection/exenteration, small bowel/colonic fistula resection, and total proctocolectomy with vaginal reconstruction.

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18481146.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Gatta G, Ciccolallo L, Kunkler I, Capocaccia R, Berrino F, Coleman MP, De Angelis R, Faivre J, Lutz JM, Martinez C, Möller T, Sankila R, EUROCARE Working Group: Survival from rare cancer in adults: a population-based study. Lancet Oncol; 2006 Feb;7(2):132-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FINDINGS: Overall 5-year relative survival was good (ie, >65%) for placental choriocarcinoma (85.4% [95% CI 81.4-89.5]), thyroid medullary carcinoma (72.4% [69.2-75.5]), ovarian germ-cell cancer (73.0% [70.0-76.0]), lung carcinoid (70.1% [67.3-72.9]), and cervical adenocarcinoma (65.5% [64.3-66.6]); intermediate (ie, 35-65%) for testicular cancer at age 65 years or older (64.0% [59.3-68.7]), sarcoma of extremities (60.0% [58.9-61.2]), digestive-system endocrine cancers (55.6% [54.9-56.3]), anal squamous-cell carcinoma (53.1% [51.5-54.8]), and uterine sarcoma (43.5% [42.0-44.9]); low for carcinoma of adrenal-gland cortex (32.7% [28.3-37.2]) and bladder squamous-cell carcinoma (20.4% [18.8-22.0]); and poor for angiosarcoma of liver (6.4% [1.8-11.0]) and mesothelioma (4.7% [4.3-5.2]).
  • Survival significantly improved over time for ovarian germ-cell cancer, sarcomas of extremities, digestive-system endocrine tumours, anal squamous-cell carcinoma, and angiosarcoma of liver.

  • MedlinePlus Health Information. consumer health - Rare Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16455477.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


34. Kalt I, Borodianskiy-Shteinberg T, Schachor A, Sarid R: GLTSCR2/PICT-1, a putative tumor suppressor gene product, induces the nucleolar targeting of the Kaposi's sarcoma-associated herpesvirus KS-Bcl-2 protein. J Virol; 2010 Mar;84(6):2935-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLTSCR2/PICT-1, a putative tumor suppressor gene product, induces the nucleolar targeting of the Kaposi's sarcoma-associated herpesvirus KS-Bcl-2 protein.
  • KS-Bcl-2, encoded by Kaposi's sarcoma-associated herpesvirus (KSHV), is a structural and functional homologue of the Bcl-2 family of apoptosis regulators.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2001 May;75(10):4843-53 [11312356.001]
  • [Cites] J Pathol. 2008 Oct;216(2):218-24 [18729076.001]
  • [Cites] J Virol. 2002 Mar;76(5):2551-6 [11836434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3428-33 [11904405.001]
  • [Cites] Genes Dev. 2002 Oct 1;16(19):2465-78 [12368257.001]
  • [Cites] Mol Biol Cell. 2002 Nov;13(11):4100-9 [12429849.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Trends Cell Biol. 2003 Sep;13(9):478-83 [12946627.001]
  • [Cites] Brain Res. 2004 Mar 19;1001(1-2):133-42 [14972662.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):45300-3 [15355975.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):690-4 [9012846.001]
  • [Cites] Nat Med. 1997 Mar;3(3):293-8 [9055856.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13829-34 [9153240.001]
  • [Cites] J Virol. 1999 May;73(5):3810-7 [10196275.001]
  • [Cites] Genomics. 2000 Feb 15;64(1):44-50 [10708517.001]
  • [Cites] J Virol. 2000 Jun;74(11):5024-31 [10799576.001]
  • [Cites] Mol Cell. 2000 Jul;6(1):31-40 [10949025.001]
  • [Cites] Nat Cell Biol. 2000 Nov;2(11):819-25 [11056537.001]
  • [Cites] Genes Dev. 1999 Aug 1;13(15):1899-911 [10444588.001]
  • [Cites] Anal Biochem. 2005 Jan 1;336(1):138-40 [15582570.001]
  • [Cites] Nature. 2005 Jan 6;433(7021):77-83 [15635413.001]
  • [Cites] Biochem J. 2005 May 1;387(Pt 3):659-67 [15554878.001]
  • [Cites] Cell Cycle. 2005 Apr;4(4):590-6 [15876860.001]
  • [Cites] Crit Rev Clin Lab Sci. 2005;42(2):101-53 [15941082.001]
  • [Cites] Cell. 2005 Sep 23;122(6):927-39 [16179260.001]
  • [Cites] Arch Virol. 2005 Nov;150(11):2387-95 [15883654.001]
  • [Cites] Nat Cell Biol. 2006 Jul;8(7):688-99 [16799551.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1318-24 [16741528.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1339-50 [16763614.001]
  • [Cites] Mol Biol Cell. 2006 Nov;17(11):4888-95 [16971513.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jul;8(7):574-85 [17519961.001]
  • [Cites] Oncogene. 2007 Aug 30;26(40):5851-65 [17369848.001]
  • [Cites] Cell Death Differ. 2007 Nov;14(11):1872-9 [17657248.001]
  • [Cites] Virology. 2008 Feb 5;371(1):14-31 [17963810.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):580-8 [18084238.001]
  • [Cites] Mol Cell. 2008 Jun 20;30(6):678-88 [18570871.001]
  • [Cites] Curr Biol. 2008 Jul 8;18(13):933-42 [18571408.001]
  • [Cites] FEBS J. 2008 Aug;275(16):4164-78 [18631361.001]
  • [Cites] J Virol. 2002 Mar;76(5):2469-79 [11836425.001]
  • (PMID = 20042497.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLTSCR2 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Recombinant Fusion Proteins; 0 / Tumor Suppressor Proteins; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2826064
  •  go-up   go-down


35. Hunt DL, Cheng C, Pounds S: The Beta-Binomial Distribution for Estimating the Number of False Rejections in Microarray Gene Expression Studies. Comput Stat Data Anal; 2009 Mar 15;53(5):1688-1700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As an example, this method is also used to perform an analysis that compares the gene expression of soft tissue sarcoma samples to normal tissue samples.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20352014.001).
  • [ISSN] 0167-9473
  • [Journal-full-title] Computational statistics & data analysis
  • [ISO-abbreviation] Comput Stat Data Anal
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA021765-309003; United States / NCI NIH HHS / CA / P30 CA021765; United States / NIGMS NIH HHS / GM / U01 GM061374; United States / NIGMS NIH HHS / GM / U01 GM061393
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] Netherlands
  •  go-up   go-down


36. Bonnet F, Chêne G: Evolving epidemiology of malignancies in HIV. Curr Opin Oncol; 2008 Sep;20(5):534-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the introduction of combination antiretroviral therapy, the incidence of Kaposi's sarcoma and cerebral lymphoma (among AIDS-defining cancers) decreased in parallel with AIDS-defining infections, whereas the incidence of systemic non-Hodgkin's lymphoma and cervical cancer decreased less than others and remains higher in HIV-infected patients than in the general population.
  • These malignancies include Hodgkin's disease, lung, anal, head and neck cancers, hemopathies, and conjunctival cancers.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106656.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 75
  •  go-up   go-down


37. Bartee E, McCormack A, Früh K: Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog; 2006 Oct;2(10):e107
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For instance, the K5 modulator of immune recognition (MIR2) from Kaposi sarcoma-associated herpesvirus prevents activation of cytotoxic T cells, natural killer cells, and natural killer T cells by downregulating major histocompatibility complex (MHC) class I molecules, the MHC-like molecule CD1, the cell adhesion molecules ICAM-1 and PECAM, and the co-stimulatory molecule B7.2.

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biol Cell. 2000 Jan;11(1):227-39 [10637304.001]
  • [Cites] J Virol. 1999 Aug;73(8):6892-902 [10400787.001]
  • [Cites] J Virol. 2000 Jun;74(11):5300-9 [10799607.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6 [10859362.001]
  • [Cites] Cell. 2000 Sep 1;102(5):549-52 [11007473.001]
  • [Cites] Immunity. 2000 Sep;13(3):365-74 [11021534.001]
  • [Cites] J Clin Invest. 2001 Jun;107(12):1599-606 [11413168.001]
  • [Cites] Cell. 2001 Oct 5;107(1):55-65 [11595185.001]
  • [Cites] Virology. 2001 Sep 30;288(2):369-78 [11601908.001]
  • [Cites] Immunity. 2001 Oct;15(4):627-36 [11672544.001]
  • [Cites] J Cell Biol. 2001 Dec 24;155(7):1265-73 [11756476.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6124-30 [11751860.001]
  • [Cites] J Virol. 2002 Mar;76(6):2912-23 [11861858.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1638-49 [11927548.001]
  • [Cites] EMBO J. 2002 May 15;21(10):2418-29 [12006494.001]
  • [Cites] Mol Cell Proteomics. 2002 May;1(5):376-86 [12118079.001]
  • [Cites] Curr Top Microbiol Immunol. 2002;269:101-15 [12224504.001]
  • [Cites] J Biol Chem. 2002 Sep 20;277(38):35071-9 [12121982.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] J Virol. 2003 Jan;77(2):1427-40 [12502858.001]
  • [Cites] Methods. 2003 Feb;29(2):124-30 [12606218.001]
  • [Cites] Nat Biotechnol. 2003 Mar;21(3):315-8 [12577067.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):14657-68 [12582153.001]
  • [Cites] J Exp Med. 2003 May 19;197(10):1245-53 [12756263.001]
  • [Cites] Nat Biotechnol. 2003 Aug;21(8):921-6 [12872131.001]
  • [Cites] Traffic. 2003 Oct;4(10):694-709 [12956872.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36718-25 [12855681.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12735-40 [14557538.001]
  • [Cites] Anal Chem. 2003 Dec 1;75(23):6648-57 [14640741.001]
  • [Cites] J Virol. 2004 Feb;78(3):1109-20 [14722266.001]
  • [Cites] Eur J Immunol. 2004 Apr;34(4):930-40 [15048703.001]
  • [Cites] Mol Cell Proteomics. 2004 Jul;3(7):729-35 [15102926.001]
  • [Cites] Nat Biotechnol. 2004 Aug;22(8):985-92 [15258593.001]
  • [Cites] J Immunol. 2004 Aug 15;173(4):2262-70 [15294938.001]
  • [Cites] Biochim Biophys Acta. 2004 Aug 23;1693(2):81-9 [15313010.001]
  • [Cites] J Immunol. 1989 Oct 15;143(8):2439-47 [2794503.001]
  • [Cites] Res Virol. 1992 Jan-Feb;143(1):52-5 [1565858.001]
  • [Cites] J Virol. 1992 Dec;66(12):7193-200 [1433512.001]
  • [Cites] Anal Chem. 1995 Apr 15;67(8):1426-36 [7741214.001]
  • [Cites] Genomics. 1995 Apr 10;26(3):527-34 [7607676.001]
  • [Cites] Cell. 1996 Mar 8;84(5):769-79 [8625414.001]
  • [Cites] Anal Chem. 1995 Sep 15;67(18):3202-10 [8686885.001]
  • [Cites] J Exp Med. 1997 Apr 7;185(7):1295-305 [9104816.001]
  • [Cites] Eur J Immunol. 1997 Jun;27(6):1469-78 [9209500.001]
  • [Cites] Nature. 1998 Jan 22;391(6665):397-401 [9450757.001]
  • [Cites] Biochem Biophys Res Commun. 1999 May 19;258(3):583-91 [10329429.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]
  • [Cites] Mol Biol Cell. 2005 Apr;16(4):1696-710 [15689499.001]
  • [Cites] J Proteome Res. 2005 Mar-Apr;4(2):400-9 [15822916.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1369-78 [15864354.001]
  • [Cites] J Cell Biol. 2005 Jul 18;170(2):177-82 [16009722.001]
  • [Cites] Immunol Rev. 2005 Oct;207:112-25 [16181331.001]
  • [Cites] Mol Cell Proteomics. 2005 Nov;4(11):1697-709 [16088002.001]
  • [Cites] Trends Biotechnol. 2005 Dec;23(12):598-604 [16202464.001]
  • [Cites] Mol Cell Proteomics. 2006 Jan;5(1):157-71 [16215274.001]
  • [Cites] Nat Chem Biol. 2005 Oct;1(5):252-62 [16408053.001]
  • [Cites] J Biochem. 2006 Jan;139(1):137-45 [16428329.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3212-20 [16352806.001]
  • [Cites] Mol Cell. 2006 Apr 21;22(2):193-204 [16630889.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1932-40 [16601245.001]
  • [Cites] EMBO J. 2000 Mar 1;19(5):870-81 [10698929.001]
  • (PMID = 17238276.001).
  • [ISSN] 1553-7374
  • [Journal-full-title] PLoS pathogens
  • [ISO-abbreviation] PLoS Pathog.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / T32 AI007472; United States / NIAID NIH HHS / AI / T32AI007472; United States / NCI NIH HHS / CA / R21 CA109674; United States / NIAID NIH HHS / AI / R01 CA/AI 09401; United States / NCI NIH HHS / CA / R21 CA 109674-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ALCAM protein, human; 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / BST2 protein, human; 0 / CD6 antigen; 0 / Cell Adhesion Molecules, Neuronal; 0 / Fetal Proteins; 0 / GPI-Linked Proteins; 0 / Immediate-Early Proteins; 0 / K5 protein, Human herpesvirus 8; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / Qa-SNARE Proteins
  • [Other-IDs] NLM/ PMC1626102
  •  go-up   go-down


38. Fuchs B, Mahlum E, Halder C, Maran A, Yaszemski M, Bode B, Bolander M, Sarkar G: High expression of tumor endothelial marker 7 is associated with metastasis and poor survival of patients with osteogenic sarcoma. Gene; 2007 Sep 15;399(2):137-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of tumor endothelial marker 7 is associated with metastasis and poor survival of patients with osteogenic sarcoma.
  • Our objective is to identify genes regulating metastasis of osteogenic sarcoma (OGS) since metastasis is the primary cause of mortality among patients with OGS.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6649-55 [11559528.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3750-9 [11325848.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):289-300 [12001990.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):89-96 [12027580.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):498-505 [12492492.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):55-63 [12509767.001]
  • [Cites] J Cell Biochem. 2003 Feb 1;88(2):408-17 [12520544.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):411-21 [12778131.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Cancer Lett. 2003 Jul 30;198(1):1-20 [12893425.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6524-36 [14528277.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2447-56 [14635080.001]
  • [Cites] Curr Opin Oncol. 2004 Jan;16(1):44-9 [14685092.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 [14685170.001]
  • [Cites] Chin Med J (Engl). 2004 Jan;117(1):94-8 [14733782.001]
  • [Cites] Nat Med. 2004 Feb;10(2):182-6 [14704791.001]
  • [Cites] Cancer. 1971 Feb;27(2):397-402 [5100401.001]
  • [Cites] N Engl J Med. 1986 Jun 19;314(25):1600-6 [3520317.001]
  • [Cites] Pediatr Clin North Am. 1997 Aug;44(4):973-89 [9286295.001]
  • [Cites] Mol Biotechnol. 1997 Oct;8(2):135-7 [9406183.001]
  • [Cites] N Engl J Med. 1999 Jul 29;341(5):342-52 [10423470.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):739-52 [10487832.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8507-11 [15574754.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] Anal Biochem. 2000 Nov 1;286(1):91-8 [11038279.001]
  • [Cites] Gene. 2000 Nov 27;258(1-2):155-63 [11111053.001]
  • [Cites] Semin Cancer Biol. 2001 Oct;11(5):327-37 [11562175.001]
  • (PMID = 17560052.001).
  • [ISSN] 0378-1119
  • [Journal-full-title] Gene
  • [ISO-abbreviation] Gene
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR047974-01A1; United States / NIAMS NIH HHS / AR / R01 AR047974-03; United States / NIAMS NIH HHS / AR / AR47974; United States / NIAMS NIH HHS / AR / R01 AR047974-02; United States / NIAMS NIH HHS / AR / AR047974-05; United States / NIAMS NIH HHS / AR / AR047974-03; United States / NIAMS NIH HHS / AR / R01 AR047974-05; United States / NIAMS NIH HHS / AR / AR047974-04; United States / NIAMS NIH HHS / AR / AR047974-02; United States / NIAMS NIH HHS / AR / R01 AR047974; United States / NIAMS NIH HHS / AR / AR047974-01A1; United States / NIAMS NIH HHS / AR / R01 AR047974-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / PLXDC1 protein, human; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, Cell Surface
  • [Other-IDs] NLM/ NIHMS29184; NLM/ PMC2066185
  •  go-up   go-down


39. Oue T, Fukuzawa M, Okita H, Mugishima H, Horie H, Hata J, Saito M, Nozaki M, Chin M, Nakadate H, Hinotsu S, Koshinaga T, Kaneko Y, Kitano Y, Tanaka Y, Japan Wilms Tumor Study (JWiTS) Group: Outcome of pediatric renal tumor treated using the Japan Wilms Tumor Study-1 (JWiTS-1) protocol: a report from the JWiTS group. Pediatr Surg Int; 2009 Nov;25(11):923-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central pathological diagnosis and follow-up data were available in 210 cases.
  • RESULTS: Five-year overall survival (OS) rate was 91.1% for nephroblastoma, 72.9% for clear cell sarcoma of the kidney (CCSK), and 22.2% for rhabdoid tumor of the kidney (RTK).
  • [MeSH-major] Kidney Neoplasms / therapy. Rhabdoid Tumor / therapy. Sarcoma, Clear Cell / therapy. Wilms Tumor / therapy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1981 Jul;12(7):646-57 [7275104.001]
  • [Cites] Med Pediatr Oncol. 1994;22(4):221-7 [8107651.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2554-62 [16904312.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):311-9 [11332141.001]
  • [Cites] Lancet. 2004 Oct 2-8;364(9441):1229-35 [15464183.001]
  • [Cites] Am J Surg Pathol. 1989 Jun;13(6):439-58 [2543225.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3719-24 [11533093.001]
  • [Cites] Lifetime Data Anal. 2007 Dec;13(4):463-70 [18027087.001]
  • [Cites] J Urol. 1991 Aug;146(2 ( Pt 2)):514-8 [1650403.001]
  • [Cites] J Urol. 1987 Oct;138(4 Pt 2):968-73 [2821293.001]
  • [Cites] Cancer. 1984 Dec 15;54(12):2978-87 [6093989.001]
  • [Cites] Cancer. 1978 May;41(5):1937-48 [206343.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):292-7 [10024113.001]
  • [Cites] Curr Probl Cancer. 2005 Sep-Oct;29(5):221-60 [16216623.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Aug;47(8):712-27 [18464243.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9138-45 [16172460.001]
  • [Cites] J Pediatr Surg. 1977 Oct;12(5):631-8 [72143.001]
  • [Cites] Cancer. 1976 Aug;38(2):633-46 [184912.001]
  • [Cites] Mol Carcinog. 2008 Sep;47(9):660-6 [18286482.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7312-21 [16129848.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2132-7 [7931484.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jun;45(6):592-601 [16518847.001]
  • (PMID = 19701757.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


40. Sánchez del Monte J, Hernández Guerrero A, Sobrino Cossio S, Lárraga Octavio A, Sánchez Benítez G, López Blanco P, Elguero Pineda E: [Clinical manifestations and endoscopic characteristics of Kaposi's sarcoma in patients with acquired immunodeficiency syndrome]. Rev Gastroenterol Mex; 2005 Oct-Dec;70(4):416-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical manifestations and endoscopic characteristics of Kaposi's sarcoma in patients with acquired immunodeficiency syndrome].
  • [Transliterated title] Manifestaciones clinicas y características endoscópicas del sarcoma de Kaposi en pacientes con síndrome de inmunodeficiencia adquirida.
  • BACKGROUND: Kaposi sarcoma may be the initial manifestation of immunodeficiency acquired syndrome (AIDS )in 30% of patients.
  • METHOD: 12 consecutive cases with AIDS and Kaposi sarcoma.
  • The distribution of Kaposi sarcoma was as follows: hard palate 7, soft palate 2, larynx 3, esophagus 2, stomach 10, duodenum 2, colon 5 and anal conduct 1.
  • The biopsy was positive to Kaposi sarcoma in at least one lesion of each patient.
  • CONCLUSIONS: The Kaposi sarcoma appears as a multiple lesion with diverse aspect and colors that go from purple to blue or red.
  • There is correlation between a high number of Kaposi sarcoma lesions, affected organs, immunologic status and mortality.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Gastrointestinal Neoplasms / etiology. Sarcoma, Kaposi / etiology

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058981.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


41. Dhir AA, Sawant S, Dikshit RP, Parikh P, Srivastava S, Badwe R, Rajadhyaksha S, Dinshaw KA: Spectrum of HIV/AIDS related cancers in India. Cancer Causes Control; 2008 Mar;19(2):147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: No case of Kaposi's sarcoma was observed.
  • In males, PIR was increased for anal cancer (PIR = 10.3, 95%CI 4.30-24.83), Hodgkin's disease, testicular cancer, colon cancer, and few head and neck cancer sites.
  • Among females, the PIRs for cervical cancer (PIR = 4.1, 95%CI 2.90-5.75), vaginal cancer (PIR = 7.7, 95%CI 2.48-23.85), and anal cancer (PIR = 6.5, 95%CI 0.91-45.88) were increased.
  • CONCLUSIONS: The absence of Kaposi's sarcoma and increased PIRs for certain non-AIDS defining cancers among HIV infected cancer cases indicates a different spectrum of HIV associated malignancies in this region.


42. Dresang LR, Vereide DT, Sugden B: Identifying sites bound by Epstein-Barr virus nuclear antigen 1 (EBNA1) in the human genome: defining a position-weighted matrix to predict sites bound by EBNA1 in viral genomes. J Virol; 2009 Apr;83(7):2930-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This PWM helped identify additional DNA-binding sites for EBNA1 in the genomes of EBV, Kaposi's sarcoma-associated herpesvirus, and cercopithecine herpesvirus 15 (CeHV-15) (also called herpesvirus papio 15).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2000 Jun;118(6):1031-8 [10833477.001]
  • [Cites] Bioinformatics. 1998;14(1):48-54 [9520501.001]
  • [Cites] J Virol. 2001 Jul;75(13):5796-811 [11390581.001]
  • [Cites] J Virol. 2001 Nov;75(22):10603-11 [11602702.001]
  • [Cites] Intervirology. 2001;44(5):271-82 [11684888.001]
  • [Cites] J Virol. 2002 Jan;76(1):421-6 [11739708.001]
  • [Cites] Virology. 2003 Jul 5;311(2):263-74 [12842617.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(19):6901-8 [12972608.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14269-74 [14603034.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]
  • [Cites] Genome Res. 2004 Jun;14(6):1188-90 [15173120.001]
  • [Cites] Trends Mol Med. 2004 Jul;10(7):331-6 [15242681.001]
  • [Cites] Biomedicine. 1975 Jul;22(4):276-84 [179629.001]
  • [Cites] Int J Cancer. 1977 Oct 15;20(4):486-94 [199543.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Jul;77(7):4251-5 [6933474.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jun;81(12):3806-10 [6328526.001]
  • [Cites] Nature. 1984 Jul 19-25;310(5974):207-11 [6087149.001]
  • [Cites] Int J Cancer. 1985 Nov 15;36(5):545-7 [4055129.001]
  • [Cites] Mol Cell Biol. 1985 Oct;5(10):2533-42 [3016506.001]
  • [Cites] J Virol. 1986 Dec;60(3):1159-62 [3023667.001]
  • [Cites] Mol Cell Biol. 1986 Nov;6(11):3838-46 [3025615.001]
  • [Cites] Anal Biochem. 1987 Jul;164(1):44-52 [2823633.001]
  • [Cites] J Virol. 1989 Jun;63(6):2644-9 [2542577.001]
  • [Cites] J Virol. 1989 Jun;63(6):2657-66 [2542579.001]
  • [Cites] J Virol. 1990 May;64(5):2369-79 [2157891.001]
  • [Cites] J Virol. 1990 Jun;64(6):2876-83 [2159548.001]
  • [Cites] Nucleic Acids Res. 1990 Oct 25;18(20):6097-100 [2172928.001]
  • [Cites] J Biol Chem. 1991 Apr 25;266(12):7819-26 [1850421.001]
  • [Cites] J Virol. 1992 Jan;66(1):489-95 [1309258.001]
  • [Cites] J Virol. 1992 Aug;66(8):4654-61 [1321268.001]
  • [Cites] EMBO J. 1998 Nov 2;17(21):6394-403 [9799247.001]
  • [Cites] J Virol. 1999 Mar;73(3):1980-9 [9971778.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3349-59 [10207059.001]
  • [Cites] J Clin Pathol. 1965 May;18:261-73 [14304234.001]
  • [Cites] Mol Cell Biol. 2006 Feb;26(3):1124-34 [16428463.001]
  • [Cites] Genome Res. 2006 Apr;16(4):466-76 [16533912.001]
  • [Cites] Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W369-73 [16845028.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):22273-7 [10801810.001]
  • [Cites] Oncogene. 2007 Jun 14;26(28):4135-47 [17486072.001]
  • [Cites] Blood. 2008 Jan 1;111(1):292-301 [17720884.001]
  • [Cites] J Virol. 2008 Feb;82(4):1679-87 [18077719.001]
  • [Cites] J Virol. 2008 Jun;82(12):5693-702 [18385243.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9639-44 [18621728.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):6963-8 [18757410.001]
  • [Cites] Nature. 1992 Oct 8;359(6395):505-12 [1328886.001]
  • [Cites] J Virol. 1995 Apr;69(4):2633-6 [7884916.001]
  • [Cites] Cell. 1995 Oct 6;83(1):39-46 [7553871.001]
  • [Cites] Proc Int Conf Intell Syst Mol Biol. 1994;2:28-36 [7584402.001]
  • [Cites] Cell. 1996 Mar 8;84(5):791-800 [8625416.001]
  • [Cites] Intervirology. 1995;38(3-4):195-205 [8682617.001]
  • [Cites] J Virol. 1996 Sep;70(9):5758-68 [8709191.001]
  • [Cites] Virology. 1996 Aug 1;222(1):1-13 [8806482.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):375-82 [9033642.001]
  • [Cites] Nucleic Acids Res. 1997 Dec 15;25(24):4876-82 [9396791.001]
  • [Cites] J Virol. 1998 Jun;72(6):4657-66 [9573229.001]
  • [Cites] J Virol. 1998 Jul;72(7):6181-5 [9621086.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14188-93 [16966603.001]
  • (PMID = 19129441.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA022443; United States / NCI NIH HHS / CA / R01 CA133027
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2655553
  •  go-up   go-down


43. Potthoff A, Brockmeyer NH: [HIV-associated tumors]. Hautarzt; 2006 Nov;57(11):988, 990-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the beginning of the HIV epidemic, Kaposi sarcoma was a common stigma in AIDS patients and one of the leading causes of death.
  • While Kaposi sarcoma is seen less frequently since the introduction of antiretroviral therapy, lymphoma and other malignancies are an increasing therapeutic challenge.
  • The incidence of HPV-related anal carcinoma and its precursor lesions is rising so dramatically that screening programs as they are already established for cervical carcinoma should be implemented.
  • [MeSH-major] HIV Infections / complications. Neoplasms / etiology. Sarcoma, Kaposi / etiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. Adult. Antiretroviral Therapy, Highly Active. Anus Neoplasms / etiology. Carcinoma, Hepatocellular / etiology. Female. HIV Seropositivity / complications. Humans. Liver Neoplasms / etiology. Lung Neoplasms / drug therapy. Lung Neoplasms / etiology. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / etiology. Male. Middle Aged. Papillomavirus Infections / complications. Risk Factors. Skin Neoplasms / etiology. Smoking / adverse effects. Uterine Cervical Neoplasms / etiology


44. Clifford GM, Franceschi S: Cancer risk in HIV-infected persons: influence of CD4(+) count. Future Oncol; 2009 Jun;5(5):669-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whereas Kaposi sarcoma and non-Hodgkin lymphoma were recognised as AIDS-defining illnesses early in the HIV epidemic, the influence of declining CD4(+) count on other infection-related cancers has taken longer to establish, undoubtedly because the association is weaker and the dose-response relationship is less steep.
  • However, following improved survival made possible by combined antiretroviral therapy, declining CD4(+) count starts showing an impact on the natural history of various carcinogenic infections and on the risk for an increasingly wide range of cancers, including Hodgkin lymphoma, cervical, anal and liver cancers.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519206.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 91
  •  go-up   go-down


45. Vidarsdóttir H, Möller PH, Tryggvason G, Kjartansson S, Jónasson JG: [Gastrointestinal Stromal Tumour (GIST). Case report]. Laeknabladid; 2005 Feb;91(2):177-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 1987 a 73 year old man was diagnosed with a malignant sarcoma of the anus.
  • Fourteen years later the original diagnoses of the specimen was reviewed and the diagnosis was changed to GIST (gastrointestinal stromal tumour).
  • This diagnosis was confirmed with appropriate immunohistochemical staining on the tumour tissue.
  • This is the first case of GIST in the anus diagnosed in Iceland.
  • [MeSH-major] Anus Neoplasms / diagnosis. Gastrointestinal Stromal Tumors / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Iceland. Immunohistochemistry. Leiomyosarcoma / diagnosis. Male

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155313.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


46. Casper C, Carrell D, Miller KG, Judson FD, Meier AS, Pauk JS, Morrow RA, Corey L, Wald A, Celum C: HIV serodiscordant sex partners and the prevalence of human herpesvirus 8 infection among HIV negative men who have sex with men: baseline data from the EXPLORE Study. Sex Transm Infect; 2006 Jun;82(3):229-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a multivariate model, reporting more than the median number of lifetime sex partners (OR 2.2, p = 0.03) or lifetime sex partners of unknown HIV status (OR 1.7, p = 0.03), and the performance of oro-anal sex ("rimming") on partners whose HIV status is unknown (OR 2.7, p = 0.04) were independently associated with HHV-8 infection.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2002 Mar 13;287(10):1295-300 [11886321.001]
  • [Cites] Sex Transm Dis. 2001 Mar;28(3):176-83 [11289201.001]
  • [Cites] J Clin Microbiol. 2002 Oct;40(10):3822-5 [12354890.001]
  • [Cites] Am J Public Health. 2003 Jun;93(6):926-32 [12773357.001]
  • [Cites] AIDS. 2003 Aug 15;17(12):1717-30 [12891058.001]
  • [Cites] J Virol. 2004 Apr;78(8):4074-84 [15047824.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):233-8 [15076237.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):632-5 [1347337.001]
  • [Cites] Am J Epidemiol. 1993 Aug 15;138(4):256-65 [8356966.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] J Leukoc Biol. 2001 Apr;69(4):639-44 [11310851.001]
  • [Cites] Rev Med Virol. 2002 Jan-Feb;12(1):47-63 [11787083.001]
  • [Cites] J Infect Dis. 2002 Apr 1;185(7):990-3 [11920325.001]
  • [Cites] Clin Infect Dis. 1996 Aug;23(2):406-7 [8842293.001]
  • [Cites] Lancet. 1996 Oct 26;348(9035):1133-8 [8888167.001]
  • [Cites] J Infect Dis. 1997 Jul;176(1):94-102 [9207354.001]
  • [Cites] J Virol. 1997 Sep;71(9):7083-7 [9261440.001]
  • [Cites] J Infect Dis. 1998 Jan;177(1):213-6 [9419191.001]
  • [Cites] Int J Cancer. 1998 Aug 12;77(4):543-8 [9679756.001]
  • [Cites] J Infect Dis. 1998 Dec;178(6):1610-5 [9815212.001]
  • [Cites] Adv Cancer Res. 1999;76:121-60 [10218100.001]
  • [Cites] Am J Epidemiol. 2000 Feb 1;151(3):213-24 [10670545.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1369-77 [11070101.001]
  • [Cites] Epidemiol Infect. 2000 Dec;125(3):671-5 [11218216.001]
  • [Cites] J Infect Dis. 1999 Oct;180(4):1010-7 [10479125.001]
  • (PMID = 16731675.001).
  • [ISSN] 1368-4973
  • [Journal-full-title] Sexually transmitted infections
  • [ISO-abbreviation] Sex Transm Infect
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U19 AI031448; United States / NIAID NIH HHS / AI / U19 AI31448; United States / NIAID NIH HHS / AI / P01 AI030731; United States / NIAID NIH HHS / AI / K23 AI054162; United States / NIAID NIH HHS / AI / P01 AI30731
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2564745
  •  go-up   go-down


47. Hayashi T, Nakamura T, Nakamura S, Kurachi K, Fukazawa A, Nakamura K, Nakajima A, Suzuki S, Konno H: Granulocytic sarcoma presenting as a thrombosed external hemorrhoid in a patient with myelodysplastic syndrome overt leukemia. Clin J Gastroenterol; 2008 Dec;1(4):145-147
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma presenting as a thrombosed external hemorrhoid in a patient with myelodysplastic syndrome overt leukemia.
  • A 67-year-old Japanese man complained of a painful lump in his anus.
  • A solid lump measuring 1.0 cm in diameter was detected in the anal verge.
  • Under a diagnosis of a thrombosed external hemorrhoid, thrombectomy was performed under local anesthesia.
  • Finally, the diagnosis of granulocytic sarcoma (GS) was made.
  • Though it is well known that perianal complications occur quite often in patients with leukemia, it is unusual for a diagnosis of GS of the anus to be definitely established.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Cancer. 1986 Dec 15;58(12):2697-709 [3465429.001]
  • [Cites] Dis Colon Rectum. 2003 Sep;46(9):1226-31 [12972967.001]
  • [Cites] Cancer. 1973 Jan;31(1):149-52 [4509385.001]
  • [Cites] Cancer. 1973 Jun;31(6):1315-27 [4513690.001]
  • [Cites] Cancer Res. 1954 Mar;14(3):157-62 [13150326.001]
  • [Cites] Leuk Lymphoma. 1996 Mar;21(1-2):153-9 [8907283.001]
  • [Cites] Br J Surg. 2006 Mar;93(3):362-8 [16470713.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):690-7 [8478662.001]
  • [Cites] Surg Gynecol Obstet. 1992 Apr;174(4):302-4 [1553609.001]
  • [Cites] Blood. 1973 Nov;42(5):721-8 [4518064.001]
  • (PMID = 26193692.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Acute myeloid leukemia (AML) / Granulocytic sarcoma (GS) / Hemorrhoid / Myelodysplastic syndromes (MDS)
  •  go-up   go-down


48. Yoo HJ, Yun BR, Kwon JH, Ahn HS, Seol MA, Lee MJ, Yu GR, Yu HC, Hong B, Choi K, Kim DG: Genetic and expression alterations in association with the sarcomatous change of cholangiocarcinoma cells. Exp Mol Med; 2009 Feb 28;41(2):102-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Cholangiocarcinoma / genetics. Gene Expression Profiling. Sarcoma / genetics


49. Stewart-Maynard KM, Cruceanu M, Wang F, Vo MN, Gorelick RJ, Williams MC, Rouzina I, Musier-Forsyth K: Retroviral nucleocapsid proteins display nonequivalent levels of nucleic acid chaperone activity. J Virol; 2008 Oct;82(20):10129-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this work, complementary experimental approaches were used to characterize and compare the chaperone activities of NC proteins from four different retroviruses: HIV-1, Moloney murine leukemia virus (MLV), Rous sarcoma virus (RSV), and human T-cell lymphotropic virus type 1 (HTLV-1).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Biol. 2003 Feb 21;326(3):691-700 [12581633.001]
  • [Cites] J Mol Biol. 2003 Mar 28;327(3):571-8 [12634053.001]
  • [Cites] J Mol Biol. 2003 Apr 18;328(1):95-108 [12684000.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3406-15 [12824337.001]
  • [Cites] J Mol Biol. 2004 Mar 19;337(2):427-42 [15003457.001]
  • [Cites] J Mol Biol. 2004 Apr 2;337(4):951-68 [15033363.001]
  • [Cites] J Mol Biol. 2004 Feb 27;336(4):851-70 [15095865.001]
  • [Cites] J Mol Biol. 2004 May 7;338(4):711-23 [15099739.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2004;33:415-40 [15139820.001]
  • [Cites] J Mol Biol. 2004 Jul 30;341(1):27-36 [15312760.001]
  • [Cites] Q Rev Biophys. 1978 May;11(2):179-246 [353876.001]
  • [Cites] J Biol Chem. 1981 Aug 25;256(16):8400-6 [6267042.001]
  • [Cites] Science. 1986 Apr 25;232(4749):485-7 [2421409.001]
  • [Cites] J Biol Chem. 1987 Apr 15;262(11):4961-7 [2435721.001]
  • [Cites] J Virol. 1987 Oct;61(10):3004-12 [3041020.001]
  • [Cites] EMBO J. 1988 Jun;7(6):1777-83 [2458920.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(16):6403-7 [2385599.001]
  • [Cites] J Mol Biol. 1990 Dec 5;216(3):689-99 [2124274.001]
  • [Cites] Nucleic Acids Res. 1991 Jul 11;19(13):3533-41 [1906602.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6472-6 [1631144.001]
  • [Cites] Protein Sci. 1993 Jan;2(1):3-19 [8443588.001]
  • [Cites] Protein Sci. 1993 Feb;2(2):231-43 [8443601.001]
  • [Cites] J Biol Chem. 1993 Aug 5;268(22):16519-27 [8344933.001]
  • [Cites] Annu Rev Biochem. 1993;62:255-87 [7688943.001]
  • [Cites] J Virol. 1994 Aug;68(8):5013-8 [8035501.001]
  • [Cites] J Virol. 1994 Sep;68(9):5863-70 [8057466.001]
  • [Cites] J Biol Chem. 1994 Sep 9;269(36):22538-46 [8077202.001]
  • [Cites] J Virol. 1995 Mar;69(3):1907-12 [7853532.001]
  • [Cites] Biopolymers. 1995 Sep;36(3):345-64 [7669919.001]
  • [Cites] J Biol Chem. 1995 Sep 8;270(36):20871-4 [7545662.001]
  • [Cites] J Mol Biol. 1995 Dec 8;254(4):523-37 [7500330.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7577-81 [8755517.001]
  • [Cites] J Virol. 1996 Aug;70(8):4996-5004 [8764006.001]
  • [Cites] Mol Endocrinol. 1996 Jun;10(6):607-12 [8776720.001]
  • [Cites] Curr Top Microbiol Immunol. 1996;214:177-218 [8791728.001]
  • [Cites] Nucleic Acids Res. 1997 Mar 1;25(5):1042-9 [9023116.001]
  • [Cites] Biopolymers. 1997 Mar;41(3):301-12 [9057495.001]
  • [Cites] J Mol Biol. 1997 May 2;268(2):250-60 [9159468.001]
  • [Cites] J Virol. 1997 Jul;71(7):5178-88 [9188585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13530-5 [9391060.001]
  • [Cites] Science. 1998 Jan 16;279(5349):384-8 [9430589.001]
  • [Cites] Biopolymers. 1998 Mar;45(3):217-29 [9465785.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):459-64 [9892655.001]
  • [Cites] J Mol Biol. 1999 Mar 19;287(1):59-75 [10074407.001]
  • [Cites] Biochemistry. 1999 Mar 23;38(12):3821-30 [10090772.001]
  • [Cites] J Virol. 1999 May;73(5):4251-6 [10196321.001]
  • [Cites] J Virol. 1999 Aug;73(8):6670-9 [10400764.001]
  • [Cites] Nature. 2004 Sep 30;431(7008):586-90 [15457265.001]
  • [Cites] J Biol Chem. 2004 Oct 15;279(42):44154-65 [15271979.001]
  • [Cites] J Mol Biol. 1968 Feb 14;31(3):349-70 [5637197.001]
  • [Cites] Biopolymers. 1976 Jul;15(7):1345-75 [949539.001]
  • [Cites] J Mol Biol. 1976 Oct 25;107(2):145-58 [1003464.001]
  • [Cites] J Virol. 1998 Mar;72(3):1902-9 [9499042.001]
  • [Cites] J Mol Biol. 1998 Mar 27;277(2):225-35 [9514748.001]
  • [Cites] J Biol Chem. 1998 May 8;273(19):11463-71 [9565558.001]
  • [Cites] Biopolymers. 1997;44(3):269-82 [9591479.001]
  • [Cites] Trends Biochem Sci. 1998 Aug;23(8):297-301 [9757830.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W577-81 [15980540.001]
  • [Cites] Nucleic Acids Res. 2005;33(14):4395-403 [16077025.001]
  • [Cites] Biophys J. 2005 Sep;89(3):1941-56 [15994897.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2005;80:217-86 [16164976.001]
  • [Cites] Phys Rev Lett. 2005 Oct 7;95(15):158102 [16241765.001]
  • [Cites] Biophys J. 2005 Nov;89(5):3470-9 [16100256.001]
  • [Cites] Nucleic Acids Res. 2006;34(2):472-84 [16434700.001]
  • [Cites] Nucleic Acids Res. 2006;34(2):593-605 [16449201.001]
  • [Cites] J Mol Biol. 2006 Oct 13;363(1):244-61 [16962137.001]
  • [Cites] Biochemistry. 2006 Oct 17;45(41):12617-28 [17029416.001]
  • [Cites] Anal Biochem. 2006 Nov 15;358(2):159-70 [17034752.001]
  • [Cites] J Mol Biol. 2006 Nov 10;363(5):867-77 [16997322.001]
  • [Cites] J Mol Biol. 2006 Dec 1;364(3):496-511 [17020765.001]
  • [Cites] J Biol Chem. 2006 Dec 15;281(50):38689-96 [17050544.001]
  • [Cites] J Mol Biol. 2007 Jan 12;365(2):453-67 [17070546.001]
  • [Cites] Biopolymers. 2007 Feb 5;85(2):154-68 [17080421.001]
  • [Cites] PLoS One. 2007;2(7):e669 [17712401.001]
  • [Cites] Biochemistry. 2007 Dec 18;46(50):14650-62 [18027912.001]
  • [Cites] J Mol Biol. 2002 May 3;318(3):749-64 [12054820.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jun 28;294(5):949-55 [12074568.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8614-9 [12084921.001]
  • [Cites] Curr Opin Struct Biol. 2002 Jun;12(3):330-6 [12127451.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2002;72:223-68 [12206453.001]
  • [Cites] J Mol Biol. 2003 Jan 3;325(1):1-10 [12473448.001]
  • [Cites] J Virol. 2003 Jan;77(2):1598-603 [12502875.001]
  • [Cites] Biophys J. 1999 Sep;77(3):1547-55 [10465765.001]
  • [Cites] Biochemistry. 2005 Mar 15;44(10):3735-44 [15751950.001]
  • [Cites] J Mol Biol. 2005 May 6;348(3):549-61 [15826653.001]
  • [Cites] J Mol Biol. 2005 May 20;348(5):1059-77 [15854644.001]
  • [Cites] J Mol Biol. 2005 May 20;348(5):1113-26 [15854648.001]
  • [Cites] J Mol Biol. 2005 Jun 3;349(2):317-30 [15890198.001]
  • [Cites] J Mol Biol. 2005 Jun 24;349(5):976-88 [15907938.001]
  • [Cites] Biochemistry. 1999 Dec 21;38(51):16816-25 [10606514.001]
  • [Cites] Nucleic Acids Res. 2000 Jan 15;28(2):634-40 [10606665.001]
  • [Cites] Biopolymers. 2000 Apr 5;53(4):329-41 [10685053.001]
  • [Cites] J Mol Biol. 2000 May 26;299(1):145-56 [10860728.001]
  • [Cites] J Mol Biol. 2000 Aug 11;301(2):491-511 [10926523.001]
  • [Cites] J Virol. 2000 Oct;74(19):8785-92 [10982320.001]
  • [Cites] J Virol. 2000 Oct;74(19):8980-8 [10982342.001]
  • [Cites] Biochim Biophys Acta. 2000 Sep 29;1481(2):381-94 [11018730.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6121-6 [11344257.001]
  • [Cites] J Mol Biol. 2001 May 25;309(1):57-68 [11491301.001]
  • [Cites] J Mol Biol. 2001 Oct 5;312(5):985-97 [11580244.001]
  • [Cites] Biochemistry. 2001 Nov 13;40(45):13644-51 [11695913.001]
  • [Cites] J Mol Biol. 2001 Nov 23;314(2):217-32 [11718556.001]
  • [Cites] J Mol Biol. 2001 Dec 14;314(5):961-70 [11743714.001]
  • [Cites] Protein Eng. 2001 Dec;14(12):993-1000 [11809930.001]
  • [Cites] Acc Chem Res. 2002 Mar;35(3):159-66 [11900519.001]
  • [Cites] J Mol Biol. 2002 Mar 29;317(3):385-99 [11922672.001]
  • (PMID = 18684831.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM072396; United States / NIGMS NIH HHS / GM / F32 GM072396; United States / NIGMS NIH HHS / GM / R01 GM065056; United States / NIGMS NIH HHS / GM / GM073462; United States / NIGMS NIH HHS / GM / GM065056; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Molecular Chaperones; 0 / Nucleic Acids; 0 / Nucleocapsid Proteins; 0 / RNA, Viral
  • [Other-IDs] NLM/ PMC2566285
  •  go-up   go-down


50. Aizawa J, Sakayama K, Kamei S, Kidani T, Yamamoto H, Norimatsu Y, Masuno H: Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8. BMC Cancer; 2010;10:51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Osteosarcoma often develops micrometastases in the lung prior to diagnosis, causing a fatal outcome.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Biol. 1999 Oct 21;9(20):R776-8 [10531025.001]
  • [Cites] Int J Cancer. 2009 Dec 1;125(11):2576-85 [19551863.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):589-93 [11212254.001]
  • [Cites] Cancer Invest. 2001;19(3):292-315 [11338887.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7647-53 [11606407.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 25;290(3):1123-7 [11798192.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1466-75 [11920503.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):344-51 [11920584.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1288-94 [12006550.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):1-9 [12538445.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2172-8 [12727836.001]
  • [Cites] Toxicol Sci. 2003 Oct;75(2):314-20 [12883076.001]
  • [Cites] J Orthop Res. 2004 Nov;22(6):1168-74 [15475193.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):7022-30 [15501982.001]
  • [Cites] Anal Biochem. 1971 Jan;39(1):197-201 [5544593.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 May;82(10):3262-6 [2860667.001]
  • [Cites] Arch Pathol Lab Med. 1987 Sep;111(9):841-5 [2888448.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] Cell. 1995 Dec 15;83(6):835-9 [8521507.001]
  • [Cites] Cell. 1996 Nov 1;87(3):377-89 [8898192.001]
  • [Cites] Annu Rev Cell Dev Biol. 1996;12:335-63 [8970730.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2474-84 [9059336.001]
  • [Cites] Int J Cancer. 1998 May 4;76(3):418-22 [9579581.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8806-11 [9671760.001]
  • [Cites] Diabet Med. 1999 Mar;16(3):179-92 [10227562.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S42-51 [10357558.001]
  • [Cites] Br J Pharmacol. 2004 Dec;143(8):933-7 [15533890.001]
  • [Cites] Toxicol Sci. 2005 Apr;84(2):319-27 [15659569.001]
  • [Cites] Oncol Rep. 2005 Oct;14(4):847-52 [16142341.001]
  • [Cites] BMC Cancer. 2006;6:53 [16519808.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):702-13 [17096328.001]
  • [Cites] BMC Cancer. 2007;7:216 [18021457.001]
  • [Cites] BMC Cancer. 2008;8:47 [18261208.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:69 [19014499.001]
  • [Cites] Cancer Sci. 2009 Apr;100(4):770-7 [19469020.001]
  • [Cites] J Orthop Res. 2009 Jul;27(7):909-15 [19105229.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):572-7 [10690541.001]
  • (PMID = 20170548.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Chromans; 0 / Hypoglycemic Agents; 0 / Thiazolidinediones; EC 3.4.24.24 / Matrix Metalloproteinase 2; I66ZZ0ZN0E / troglitazone
  • [Other-IDs] NLM/ PMC2838820
  •  go-up   go-down


51. Mathew SS, Bryant PW, Burch AD: Accumulation of oxidized proteins in Herpesvirus infected cells. Free Radic Biol Med; 2010 Aug 1;49(3):383-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we show that oxidized proteins accumulate during infections with two distantly related herpesviruses, HSV-1 and Rhesus Rhadinovirus (RRV), a close relative of the Kaposi's sarcoma-associated herpesvirus (KSHV).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Free Radic Biol Med. 1999 Dec;27(11-12):1151-63 [10641706.001]
  • [Cites] Exp Eye Res. 2000 Feb;70(2):215-20 [10655147.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5746-9 [10811907.001]
  • [Cites] Methods Mol Biol. 2000;99:15-24 [10909073.001]
  • [Cites] Drug Metab Rev. 2000 Aug-Nov;32(3-4):307-26 [11139131.001]
  • [Cites] Biochimie. 2001 Mar-Apr;83(3-4):301-10 [11295490.001]
  • [Cites] Free Radic Biol Med. 2001 May 15;30(10):1171-6 [11369508.001]
  • [Cites] EMBO J. 2001 Sep 17;20(18):5280-9 [11566891.001]
  • [Cites] IUBMB Life. 2001 Dec;52(6):303-7 [11895079.001]
  • [Cites] Free Radic Biol Med. 2002 May 1;32(9):790-6 [11978480.001]
  • [Cites] Biochem Pharmacol. 2002 Sep;64(5-6):1019-26 [12213601.001]
  • [Cites] Ann N Y Acad Sci. 2002 Nov;973:488-504 [12485918.001]
  • [Cites] Trends Mol Med. 2003 Apr;9(4):169-76 [12727143.001]
  • [Cites] Virology. 2003 Jul 20;312(1):122-34 [12890626.001]
  • [Cites] Circulation. 2004 Feb 3;109(4):500-5 [14732750.001]
  • [Cites] J Virol. 2004 Jul;78(13):7175-85 [15194794.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Dec;36(12):2519-30 [15325589.001]
  • [Cites] J Virol. 1978 Sep;27(3):490-504 [212578.001]
  • [Cites] Free Radic Res Commun. 1986;1(6):361-7 [3505892.001]
  • [Cites] Methods Enzymol. 1990;186:464-78 [1978225.001]
  • [Cites] Methods Enzymol. 1994;233:346-57 [8015469.001]
  • [Cites] J Biol Chem. 1995 Feb 3;270(5):2344-51 [7836468.001]
  • [Cites] Ann Med. 1994 Dec;26(6):435-41 [7695870.001]
  • [Cites] J Neurochem. 1995 Nov;65(5):2146-56 [7595501.001]
  • [Cites] Antiviral Res. 1995 Jun;27(3):237-53 [8540746.001]
  • [Cites] J Biol Chem. 1996 Jun 28;271(26):15504-9 [8663134.001]
  • [Cites] Free Radic Biol Med. 1996;21(5):641-9 [8891667.001]
  • [Cites] FASEB J. 1997 Jun;11(7):526-34 [9212076.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):3868-78 [18652502.001]
  • [Cites] J Virol. 2009 Sep;83(18):9304-12 [19587060.001]
  • [Cites] PLoS Pathog. 2009 Oct;5(10):e1000619 [19816571.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20313-6 [9252331.001]
  • [Cites] Anal Biochem. 1999 Jan 1;266(1):48-57 [9887212.001]
  • [Cites] Arch Biochem Biophys. 1999 Feb 15;362(2):211-6 [9989929.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6223-8 [10339569.001]
  • [Cites] Free Radic Biol Med. 2004 Dec 15;37(12):2072-81 [15544925.001]
  • [Cites] Antioxid Redox Signal. 2005 Mar-Apr;7(3-4):414-22 [15706088.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11648-55 [15659387.001]
  • [Cites] EMBO J. 2005 Apr 6;24(7):1311-7 [15775985.001]
  • [Cites] J Virol. 2005 Aug;79(16):10740-9 [16051866.001]
  • [Cites] Free Radic Biol Med. 2005 Nov 1;39(9):1208-15 [16214036.001]
  • [Cites] Proteomics. 2006 Feb;6(4):1250-60 [16408314.001]
  • [Cites] J Virol. 2006 Apr;80(7):3567-81 [16537625.001]
  • [Cites] J Cell Mol Med. 2006 Apr-Jun;10(2):389-406 [16796807.001]
  • [Cites] Exp Cell Res. 2007 Jan 1;313(1):195-209 [17123510.001]
  • [Cites] J Neurovirol. 2007 Oct;13(5):416-25 [17994426.001]
  • [Cites] PLoS One. 2008;3(1):e1491 [18231578.001]
  • [Cites] J Virol. 2008 Apr;82(7):3381-90 [18234803.001]
  • [Cites] Mol Cell Biochem. 2008 Jun;313(1-2):179-86 [18414998.001]
  • [Cites] J Virol. 2008 Jul;82(13):6324-36 [18434395.001]
  • (PMID = 20441790.001).
  • [ISSN] 1873-4596
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / K22 AI062991; United States / NIAID NIH HHS / AI / K22AI062991
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HSP27 Heat-Shock Proteins; 0 / Molecular Chaperones; 0 / Proteins; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Other-IDs] NLM/ NIHMS233650; NLM/ PMC3206308
  •  go-up   go-down


52. Wagner DG, Yao JL, di Sant'Agnese PA, Cheng L, Lopez-Beltran A, Montironi R, Huang J: Soft tissue tumors of the prostate: a review. Anal Quant Cytol Histol; 2007 Dec;29(6):341-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnostic immunohistochemistry is an important adjunct to histopathology for proper diagnosis and tumor subclassification.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18225389.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


53. Kovaleva M, Bussmeyer I, Rabe B, Grötzinger J, Sudarman E, Eichler J, Conrad U, Rose-John S, Scheller J: Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display. J Virol; 2006 Sep;80(17):8510-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Viral interleukin (vIL-6) is believed to play an important role in the pathogenesis of Kaposi's sarcoma as well as primary effusion lymphoma and multicentric Castleman's disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1119-23 [8302840.001]
  • [Cites] Science. 1994 Jun 3;264(5164):1415-21 [8197455.001]
  • [Cites] Biochem J. 1994 Jun 1;300 ( Pt 2):281-90 [8002928.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1399-406 [8666898.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] J Virol. 1997 Jan;71(1):839-42 [8985427.001]
  • [Cites] J Exp Med. 1997 Feb 17;185(4):755-66 [9034153.001]
  • [Cites] Nat Biotechnol. 1997 Feb;15(2):142-5 [9035138.001]
  • [Cites] Proteins. 1997 Jan;27(1):96-109 [9037715.001]
  • [Cites] Comb Chem High Throughput Screen. 2005 Mar;8(2):117-26 [15777175.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3797-802 [16091453.001]
  • [Cites] Science. 2001 Mar 16;291(5511):2150-5 [11251120.001]
  • [Cites] Immunity. 2001 Jun;14(6):705-14 [11420041.001]
  • [Cites] Blood. 2001 Nov 15;98(10):3042-9 [11698289.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1858-63 [9490667.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3251-6 [9501249.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27213-9 [9765242.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3495-504 [9808540.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1487-95 [10029575.001]
  • [Cites] J Virol. 1999 May;73(5):4181-7 [10196314.001]
  • [Cites] Glia. 1999 May;26(3):191-200 [10340760.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] J Mol Biol. 2002 Jan 25;315(4):637-46 [11812136.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] AIDS. 2002 May 24;16(8):F9-18 [12004288.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1432-5 [12434062.001]
  • [Cites] Biochemistry. 2003 May 13;42(18):5244-52 [12731865.001]
  • [Cites] J Immunol. 2003 Sep 15;171(6):3202-9 [12960349.001]
  • [Cites] Plant J. 1999 Dec;20(5):601-10 [10652132.001]
  • [Cites] J Immunol. 2000 May 1;164(9):4672-7 [10779772.001]
  • [Cites] Nat Med. 2000 May;6(5):583-8 [10802717.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):387-94 [10830746.001]
  • [Cites] Eur J Biochem. 2000 Jun;267(12):3604-12 [10848977.001]
  • [Cites] J Exp Med. 1997 Mar 17;185(6):1005-12 [9091574.001]
  • [Cites] Immunity. 1997 Mar;6(3):315-25 [9075932.001]
  • [Cites] Annu Rev Immunol. 1997;15:797-819 [9143707.001]
  • [Cites] Science. 1997 Jun 20;276(5320):1851-4 [9188529.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19625-31 [9235971.001]
  • [Cites] FEBS Lett. 1997 Sep 15;414(3):557-61 [9323035.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1517-22 [9403701.001]
  • [Cites] Science. 1997 Dec 12;278(5345):1969-70; author reply 1972-3 [9417642.001]
  • [Cites] Blood. 1999 Aug 1;94(3):923-31 [10419883.001]
  • [Cites] J Virol. 1999 Oct;73(10):8268-78 [10482577.001]
  • [Cites] Biol Chem. 1999 Jul-Aug;380(7-8):803-13 [10494829.001]
  • [Cites] J Immunol. 1999 Oct 15;163(8):4583-9 [10510402.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2931-3 [10515899.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):51793-803 [15258150.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jan 28;326(4):724-8 [15607729.001]
  • [Cites] Mol Pathol. 2000 Apr;53(2):69-76 [10889905.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] Eur J Biochem. 2001 Jan;268(1):160-7 [11121117.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2506-12 [12791661.001]
  • [Cites] J Immunol. 2004 Feb 15;172(4):2225-31 [14764690.001]
  • [Cites] J Exp Med. 2004 Feb 16;199(4):503-14 [14970177.001]
  • [Cites] J Immunol Methods. 2004 Aug;291(1-2):93-100 [15345308.001]
  • [Cites] Immunity. 2004 Oct;21(4):491-501 [15485627.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Science. 1985 Jun 14;228(4705):1315-7 [4001944.001]
  • [Cites] Cell. 1985 Jul;41(3):727-34 [3924409.001]
  • [Cites] Gene. 1989 Apr 15;77(1):51-9 [2744487.001]
  • [Cites] Gene. 1989 Apr 15;77(1):61-8 [2744488.001]
  • [Cites] J Exp Med. 1989 Oct 1;170(4):1409-14 [2529343.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):6934-8 [2169613.001]
  • [Cites] Nature. 1990 Dec 6;348(6301):552-4 [2247164.001]
  • [Cites] Trends Biochem Sci. 1990 Dec;15(12):483-6 [2077689.001]
  • [Cites] Proteins. 1990;8(4):309-14 [1708882.001]
  • [Cites] EMBO J. 1991 Oct;10(10):2821-32 [1833184.001]
  • [Cites] J Immunol. 1992 Apr 1;148(7):2175-80 [1545125.001]
  • [Cites] J Immunol. 1992 Sep 15;149(6):2021-7 [1381393.001]
  • [Cites] Anal Biochem. 1993 May 1;210(2):425-8 [8512082.001]
  • [Cites] J Biol Chem. 1993 Oct 15;268(29):22084-91 [8408066.001]
  • [Cites] Anal Biochem. 1993 Aug 1;212(2):457-68 [8214588.001]
  • (PMID = 16912301.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Viral; 0 / Immunoglobulin Variable Region; 0 / Interleukin-6; 0 / Peptide Library; 0 / Recombinant Proteins; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC1563863
  •  go-up   go-down


54. Bower M, Palmieri C, Dhillon T: AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis; 2006 Feb;19(1):14-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Three cancers in people with HIV denote an AIDS diagnosis: Kaposi's sarcoma, high-grade B-cell non-Hodgkin's lymphoma and invasive cervical cancer.
  • RECENT FINDINGS: The incidence of both Kaposi's sarcoma and non-Hodgkin's lymphoma has declined in the era of highly active antiretroviral therapy and the outcome of both tumours has improved.
  • Moreover, highly active antiretroviral therapy alone produces a response in a majority of antiretroviral-naïve patients with Kaposi's sarcoma.
  • In contrast, highly active antiretroviral therapy has had little impact on the incidence of human papilloma virus-associated tumours (cervical and anal cancer) in people with HIV, although it may improve survival by reducing opportunistic infection deaths.
  • SUMMARY: For those with access to highly active antiretroviral therapy, the good news from the AIDS-defining cancers - particularly Kaposi's sarcoma and non-Hodgkin's lymphoma - may be balanced by the increasing numbers of non AIDS-defining cancers.
  • [MeSH-minor] Female. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / epidemiology


55. Barzegari A, Vahed SZ, Atashpaz S, Khani S, Omidi Y: Rapid and simple methodology for isolation of high quality genomic DNA from coniferous tissues (Taxus baccata). Mol Biol Rep; 2010 Feb;37(2):833-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid and simple methodology for isolation of high quality genomic DNA from coniferous tissues (Taxus baccata).
  • Various investigations have been so far performed for extraction of genomic DNA from plant tissues, in which the extracted intact DNA can be exploited for a diverse range of biological studies.
  • Extraction of high quality DNA from leathery plant tissues (e.g., coniferous organs) appears to be a critical stage.
  • Moreover, for some species such as Taxus trees, bioprocess engineering and biosynthesis of secondary metabolites (e.g., paclitaxel) is a crucial step due to the restrictions associated with extinction of these species.
  • However, extraction of intact genomic DNA from these plants still demands a rapid, easy and efficient protocol.
  • To pursue such aim, in the current work, we report on the development of a simple and highly efficient method for the extraction of DNA from Taxus baccata.
  • Based upon our protocol, interfering phenolic compounds were removed from extraction using polyvinylpyrrolidone and RNA contamination was resolved using LiCl.
  • By employing this method, high quality genomic DNA was successfully extracted from leaves of T. baccata.
  • The quality of extracted DNA was validated by various techniques such as RAPD marker, restriction digestions and pre-AFLP.
  • Upon our findings, we propose this simple method to be considered for extraction of DNA from leathery plant tissues.
  • [MeSH-major] Cell Fractionation / methods. Cloning, Molecular / methods. DNA, Plant / isolation & purification. Taxus / genetics
  • [MeSH-minor] Coniferophyta / chemistry. Coniferophyta / genetics. Genome, Plant. Nucleic Acid Amplification Techniques. Quality Control. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2000 Feb 1;278(1):86-90 [10640359.001]
  • [Cites] Evid Based Complement Alternat Med. 2007 Sep;4(3):313-9 [17965761.001]
  • [Cites] Br J Dermatol. 2008 Jun;158(6):1339-44 [18363766.001]
  • [Cites] Genet Mol Res. 2007 Mar 29;6(1):173-87 [17469067.001]
  • [Cites] Am J Bot. 2003 Feb;90(2):175-82 [21659107.001]
  • [Cites] Genet Mol Res. 2007 Oct 05;6(4):1064-71 [18273799.001]
  • [Cites] Sarcoma. 2000;4(1-2):37-45 [18521433.001]
  • [Cites] Am J Clin Oncol. 2005 Oct;28(5):508-12 [16199992.001]
  • [Cites] Nucleic Acids Res. 1997 Mar 1;25(5):1085-6 [9023124.001]
  • [Cites] Lett Appl Microbiol. 2008 Jul;47(1):8-11 [18498320.001]
  • [Cites] Biotechniques. 1996 Jun;20(6):974, 977, 979 [8780866.001]
  • [Cites] Int J Oncol. 2008 Oct;33(4):677-87 [18813780.001]
  • (PMID = 19649730.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Plant
  •  go-up   go-down


56. Bu W, Carroll KD, Palmeri D, Lukac DM: Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50/Rta lytic switch protein functions as a tetramer. J Virol; 2007 Jun;81(11):5788-806
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50/Rta lytic switch protein functions as a tetramer.
  • The Kaposi's sarcoma-associated herpesvirus open reading frame 50 (ORF50) protein (called Rta), is necessary and sufficient for reactivation of the virus from latency.
  • [MeSH-major] Herpesvirus 8, Human / chemistry. Immediate-Early Proteins / chemistry. Protein Structure, Quaternary. Sarcoma, Kaposi / virology. Trans-Activators / chemistry. Viral Proteins / chemistry. Virus Activation

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. L-Leucine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Virol. 2005 May;79(9):5640-52 [15827179.001]
  • [Cites] J Virol. 2005 Jul;79(14):8750-63 [15994769.001]
  • [Cites] Oncogene. 2005 Sep 8;24(40):6165-73 [15897867.001]
  • [Cites] Dermatology. 2001;203(1):19-23 [11549794.001]
  • [Cites] Arch Virol. 2001 Jul;146(7):1415-26 [11556717.001]
  • [Cites] J Invest Dermatol. 2001 Oct;117(4):858-63 [11676823.001]
  • [Cites] J Virol. 2001 Dec;75(24):11961-73 [11711586.001]
  • [Cites] J Virol. 2002 Mar;76(6):2634-40 [11861829.001]
  • [Cites] J Virol. 2002 Apr;76(7):3168-78 [11884541.001]
  • [Cites] J Virol. 2002 May;76(10):5000-13 [11967316.001]
  • [Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]
  • [Cites] J Infect Dis. 2002 Jun 15;185(12):1736-44 [12085319.001]
  • [Cites] J Virol. 2002 Aug;76(16):8252-64 [12134031.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(18):6321-35 [12192032.001]
  • [Cites] Eur J Immunol. 2002 Oct;32(10):2711-20 [12355422.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):8282-94 [14585985.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1632-4 [14615380.001]
  • [Cites] J Virol. 2004 Apr;78(8):4248-67 [15047839.001]
  • [Cites] AIDS. 2004 Feb 20;18(3):485-93 [15090801.001]
  • [Cites] J Virol. 2004 May;78(10):5491-9 [15113928.001]
  • [Cites] J Virol. 2004 Jul;78(13):6818-26 [15194757.001]
  • [Cites] Virology. 1999 Oct 25;263(2):436-49 [10544116.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2644-54 [15197808.001]
  • [Cites] J Virol. 2004 Aug;78(16):8615-29 [15280471.001]
  • [Cites] J Virol. 2004 Oct;78(19):10657-73 [15367633.001]
  • [Cites] Biopolymers. 1987 Sep;26(9):1587-600 [3663874.001]
  • [Cites] J Mol Biol. 1988 Jun 5;201(3):601-19 [3418712.001]
  • [Cites] Science. 1989 Jan 27;243(4890):538-42 [2911757.001]
  • [Cites] Science. 1990 Aug 24;249(4971):912-5 [2144057.001]
  • [Cites] Science. 1990 Nov 2;250(4981):646-51 [2237415.001]
  • [Cites] Science. 1990 Dec 7;250(4986):1400-3 [2147779.001]
  • [Cites] FEBS Lett. 1990 Dec 17;277(1-2):185-8 [2269352.001]
  • [Cites] J Mol Biol. 1991 Mar 20;218(2):397-412 [2010917.001]
  • [Cites] Nucleic Acids Res. 1991 May 25;19(10):2661-7 [1645863.001]
  • [Cites] Science. 1991 Oct 25;254(5031):539-44 [1948029.001]
  • [Cites] Pept Res. 1990 May-Jun;3(3):123-37 [2134057.001]
  • [Cites] Biochemistry. 1992 Jun 30;31(25):5739-46 [1610823.001]
  • [Cites] Pept Res. 1988 Sep-Oct;1(1):19-30 [2980779.001]
  • [Cites] Genes Dev. 1993 Sep;7(9):1810-23 [8370528.001]
  • [Cites] Biochem J. 1994 Jan 15;297 ( Pt 2):249-60 [8297327.001]
  • [Cites] J Mol Biol. 1994 Apr 8;237(4):500-12 [8151708.001]
  • [Cites] Cell Mol Life Sci. 2005 Dec;62(23):2771-91 [16231091.001]
  • [Cites] EMBO Rep. 2006 Jan;7(1):41-5 [16391536.001]
  • [Cites] Bioinformatics. 2006 Feb 1;22(3):356-8 [16317077.001]
  • [Cites] J Virol. 2006 Mar;80(6):2958-67 [16501105.001]
  • [Cites] J Virol. 2006 Oct;80(19):9697-709 [16973574.001]
  • [Cites] J Virol. 2006 Dec;80(24):12171-86 [17020951.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):417-22 [10662787.001]
  • [Cites] J Virol. 2000 Apr;74(8):3586-97 [10729134.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] J Clin Virol. 2000 Aug;17(2):127-36 [10942093.001]
  • [Cites] J Virol. 2000 Sep;74(18):8623-34 [10954564.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):270-4 [10969352.001]
  • [Cites] AIDS. 2000 Sep 29;14(14):2109-16 [11061651.001]
  • [Cites] Semin Cancer Biol. 2000 Oct;10(5):367-81 [11100885.001]
  • [Cites] J Virol. 2001 Jan;75(2):891-902 [11134302.001]
  • [Cites] Cell Mol Life Sci. 1999 Nov 30;56(9-10):788-806 [11212339.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(28):44-9 [11158206.001]
  • [Cites] J Virol. 2001 Feb;75(4):1909-17 [11160690.001]
  • [Cites] J Virol. 2001 Mar;75(6):2810-7 [11222705.001]
  • [Cites] J Virol. 2001 Apr;75(7):3129-40 [11238840.001]
  • [Cites] J Virol. 2001 Apr;75(7):3175-84 [11238844.001]
  • [Cites] J Virol. 2001 May;75(10):4843-53 [11312356.001]
  • [Cites] J Virol. 2001 Jul;75(13):5891-8 [11390590.001]
  • [Cites] J Virol. 2001 Aug;75(15):6786-99 [11435557.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] Anal Biochem. 1994 Mar;217(2):220-30 [8203750.001]
  • [Cites] Science. 1994 Jul 15;265(5170):386-91 [8023159.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Science. 1995 Feb 24;267(5201):1078-9 [7855583.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1498-502 [7878469.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] Protein Sci. 1995 Aug;4(8):1596-607 [8520486.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):158-63 [8548757.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Lancet. 1996 Oct 26;348(9035):1133-8 [8888167.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):11718-22 [9115224.001]
  • [Cites] J Mol Biol. 1997 Oct 17;273(1):61-74 [9367746.001]
  • [Cites] J Virol. 1998 Feb;72(2):1005-12 [9444993.001]
  • [Cites] AIDS. 1998 May 7;12(7):F45-9 [9619797.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10437-42 [9724721.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):34-8 [9928727.001]
  • [Cites] N Engl J Med. 1999 Apr 8;340(14):1063-70 [10194235.001]
  • [Cites] J Virol. 1999 Jul;73(7):6006-14 [10364352.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2004 Dec;78(24):13637-52 [15564474.001]
  • [Cites] Immunity. 2005 Jan;22(1):59-70 [15664159.001]
  • [Cites] J Virol. 2005 Feb;79(4):2420-31 [15681443.001]
  • [Cites] Virology. 2007 Mar 1;359(1):19-27 [17055026.001]
  • [Cites] J Virol. 2002 Dec;76(23):12044-54 [12414946.001]
  • [Cites] J Virol. 2002 Dec;76(24):12574-83 [12438583.001]
  • [Cites] J Virol. 2003 Jan;77(1):600-23 [12477864.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2055-67 [12612078.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] AIDS. 2003 Aug 15;17(12):1847-51 [12891072.001]
  • [Cites] J Virol. 2003 Sep;77(17):9399-411 [12915555.001]
  • [Cites] J Virol. 2003 Sep;77(17):9451-62 [12915560.001]
  • [Cites] J Virol. 2003 Sep;77(17):9590-612 [12915572.001]
  • (PMID = 17392367.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immediate-Early Proteins; 0 / ORF 50 transactivator; 0 / Rta protein, Human herpesvirus 8; 0 / Trans-Activators; 0 / Viral Proteins; 9DLQ4CIU6V / Proline; GMW67QNF9C / Leucine
  • [Other-IDs] NLM/ PMC1900300
  •  go-up   go-down


57. Dyson OF, Ford PW, Chen D, Li YQ, Akula SM: Raman tweezers provide the fingerprint of cells supporting the late stages of KSHV reactivation. J Cell Mol Med; 2009 Aug;13(8B):1920-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) has both latent and lytic phases of replication.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 2000 Mar 1;268(1):159-66 [10683338.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4516-22 [15705790.001]
  • [Cites] J Virol. 2001 Jan;75(2):891-902 [11134302.001]
  • [Cites] J Mol Biol. 2001 Mar 30;307(3):899-911 [11273709.001]
  • [Cites] Virology. 2001 Jun 5;284(2):235-49 [11384223.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1251-69 [11423257.001]
  • [Cites] Recent Results Cancer Res. 2002;159:27-37 [11785841.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1823-31 [11896614.001]
  • [Cites] Blood. 2002 Aug 1;100(3):888-96 [12130499.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4818-23 [7585513.001]
  • [Cites] Anal Chem. 2005 Jul 15;77(14):4390-7 [16013851.001]
  • [Cites] J Virol Methods. 2005 Nov;129(2):145-51 [15992938.001]
  • [Cites] Biophys J. 2006 Jan 15;90(2):648-56 [16239327.001]
  • [Cites] J Gen Virol. 2006 Mar;87(Pt 3):519-29 [16476973.001]
  • [Cites] J Gen Virol. 2006 May;87(Pt 5):1139-44 [16603514.001]
  • [Cites] Virol J. 2006;3:51 [16805914.001]
  • [Cites] J Electron Microsc (Tokyo). 2007 Jan;56(1):27-36 [17392397.001]
  • [Cites] Intervirology. 2007;50(4):245-53 [17460413.001]
  • [Cites] Virology. 2007 Sep 1;365(2):336-45 [17490703.001]
  • [Cites] PLoS One. 2007;2(8):e811 [17726541.001]
  • [Cites] PLoS Pathog. 2007 Oct 19;3(10):1388-400 [17953479.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2723-8 [17724716.001]
  • [Cites] J Clin Invest. 2004 Jan;113(1):124-36 [14702116.001]
  • [Cites] J Biomed Opt. 2003 Apr;8(2):173-8 [12683842.001]
  • [Cites] Biophys J. 2003 Jun;84(6):3968-81 [12770902.001]
  • [Cites] Biopolymers. 2003;72(4):230-40 [12833477.001]
  • [Cites] J Clin Invest. 2004 Jan;113(1):21-3 [14702103.001]
  • [Cites] Mol Cell. 2004 Mar 12;13(5):713-23 [15023341.001]
  • [Cites] Oncogene. 2004 Jul 1;23(30):5227-41 [15122343.001]
  • [Cites] Clin Chem. 2004 Sep;50(9):1597-606 [15247154.001]
  • [Cites] Ann Intern Med. 1984 Jun;100(6):866-80 [6326635.001]
  • [Cites] J Behav Med. 1985 Sep;8(3):249-60 [3003360.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(13):4987-91 [2740335.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1991 Apr;32(5):1558-61 [1849874.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6289-93 [7603984.001]
  • [Cites] Methods Enzymol. 1995;254:114-24 [8531680.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] AIDS. 1997 Sep;11(11):1327-32 [9302441.001]
  • [Cites] J Virol. 1997 Oct;71(10):7963-8 [9311888.001]
  • [Cites] J Virol. 1998 Jul;72(7):6223-7 [9621094.001]
  • [Cites] Biophys J. 1998 Jul;75(1):70-91 [9649369.001]
  • [Cites] Curr Clin Top Infect Dis. 1998;18:237-51 [9779358.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2690-8 [10082535.001]
  • [Cites] Biospectroscopy. 1999;5(3):151-67 [10380082.001]
  • [Cites] Leukemia. 2005 Jan;19(1):18-26 [15470486.001]
  • [Cites] J Virol. 2005 Feb;79(4):2626-30 [15681463.001]
  • [Cites] J Agric Food Chem. 2005 Feb 23;53(4):845-52 [15712988.001]
  • [Cites] Oncol Rep. 2005 May;13(5):837-46 [15809747.001]
  • [Cites] J Virol. 2000 Jul;74(13):5896-901 [10846070.001]
  • (PMID = 18752634.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB006483-02; United States / NIBIB NIH HHS / EB / R21 EB006483-02; United States / NIBIB NIH HHS / EB / R21 EB006483; United States / NIBIB NIH HHS / EB / R21 EB006483-01A1; United States / NIBIB NIH HHS / EB / R21EB006483; United States / NIBIB NIH HHS / EB / EB006483-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS90700; NLM/ PMC2819606
  •  go-up   go-down


58. Garrigues HJ, Rubinchikova YE, Dipersio CM, Rose TM: Integrin alphaVbeta3 Binds to the RGD motif of glycoprotein B of Kaposi's sarcoma-associated herpesvirus and functions as an RGD-dependent entry receptor. J Virol; 2008 Feb;82(3):1570-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrin alphaVbeta3 Binds to the RGD motif of glycoprotein B of Kaposi's sarcoma-associated herpesvirus and functions as an RGD-dependent entry receptor.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) envelope-associated glycoprotein B (gB) is involved in the initial steps of binding to host cells during KSHV infection. gB contains an RGD motif reported to bind the integrin alpha(3)beta(1) during virus entry.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 May 1;57(9):1682-9 [9135008.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):19794-800 [9242639.001]
  • [Cites] Int J Biochem Cell Biol. 1997 May;29(5):721-5 [9251239.001]
  • [Cites] J Virol. 1997 Dec;71(12):9764-9 [9371642.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] Annu Rev Cell Biol. 1988;4:487-525 [3058164.001]
  • [Cites] J Biol Chem. 1988 Dec 15;263(35):18726-31 [2461930.001]
  • [Cites] J Biol Chem. 1990 Feb 5;265(4):2168-72 [1688848.001]
  • [Cites] Cell. 1991 May 17;65(4):599-610 [2032285.001]
  • [Cites] J Invest Dermatol. 1992 May;98(5):764-70 [1569325.001]
  • [Cites] J Virol. 1999 Apr;73(4):3040-53 [10074154.001]
  • [Cites] Biochem Soc Symp. 1999;65:79-99 [10320934.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):24080-6 [10446179.001]
  • [Cites] J Nucl Med. 1999 Jun;40(6):1061-71 [10452325.001]
  • [Cites] J Virol. 2005 Jan;79(2):1191-206 [15613346.001]
  • [Cites] Exp Cell Res. 2005 Mar 10;304(1):317-27 [15707596.001]
  • [Cites] J Virol. 2005 Aug;79(16):10308-29 [16051824.001]
  • [Cites] J Virol. 2006 Feb;80(3):1167-80 [16414994.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1741-9 [16424204.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1921-4 [16574866.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):20932-9 [16731529.001]
  • [Cites] J Virol. 2006 Oct;80(20):10073-82 [17005685.001]
  • [Cites] Virology. 2006 Oct 10;354(1):103-15 [16879850.001]
  • [Cites] J Cell Biol. 1993 Jan;120(2):523-35 [8421064.001]
  • [Cites] J Biol Chem. 1993 Apr 25;268(12):8651-7 [8473308.001]
  • [Cites] Cell. 1993 Apr 23;73(2):309-19 [8477447.001]
  • [Cites] J Biol Chem. 1998 Jun 19;273(25):15854-9 [9624186.001]
  • [Cites] Biotechnology (N Y). 1995 Mar;13(3):265-70 [9634769.001]
  • [Cites] J Gen Virol. 1998 Jul;79 ( Pt 7):1573-91 [9680119.001]
  • [Cites] Biochemistry. 1998 Aug 4;37(31):10945-55 [9692987.001]
  • [Cites] J Cell Biol. 1998 Sep 7;142(5):1357-69 [9732295.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):21785-8 [10801897.001]
  • [Cites] J Cell Sci. 2000 Aug;113 ( Pt 16):2909-21 [10910775.001]
  • [Cites] Microsc Res Tech. 2000 Nov 1;51(3):280-301 [11054877.001]
  • [Cites] Virology. 2001 Apr 10;282(2):245-55 [11289807.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1251-69 [11423257.001]
  • [Cites] J Virol. 2001 Aug;75(16):7517-27 [11462024.001]
  • [Cites] Bioconjug Chem. 2002 Jan-Feb;13(1):128-35 [11792188.001]
  • [Cites] Chembiochem. 2000 Aug 18;1(2):107-14 [11828404.001]
  • [Cites] Cell. 2002 Feb 8;108(3):407-19 [11853674.001]
  • [Cites] Cell. 2002 Sep 20;110(6):673-87 [12297042.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6146-51 [12414640.001]
  • [Cites] BMC Biochem. 2001;2:10 [11696247.001]
  • [Cites] J Virol. 2003 Jan;77(2):1524-39 [12502866.001]
  • [Cites] J Virol. 2003 Mar;77(5):3131-47 [12584338.001]
  • [Cites] J Virol. 2003 Jun;77(11):6474-81 [12743304.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21878-85 [12676956.001]
  • [Cites] J Virol. 2003 Oct;77(19):10179-85 [12970403.001]
  • [Cites] J Biochem. 2003 Oct;134(4):497-504 [14607975.001]
  • [Cites] J Virol. 2004 Apr;78(8):4207-23 [15047836.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 5;1692(2-3):103-19 [15246682.001]
  • [Cites] J Cell Biol. 1987 Oct;105(4):1873-84 [2822727.001]
  • [Cites] J Biol Chem. 1987 Dec 25;262(36):17294-8 [3693352.001]
  • [Cites] J Biol Chem. 1994 Jan 14;269(2):960-7 [7507113.001]
  • [Cites] Science. 1994 Apr 22;264(5158):569-71 [7512751.001]
  • [Cites] Mol Biol Cell. 1994 Feb;5(2):203-15 [8019006.001]
  • [Cites] J Biol Chem. 1994 Aug 12;269(32):20233-8 [8051114.001]
  • [Cites] J Pathol. 1994 May;173(1):23-31 [7523640.001]
  • [Cites] Infect Agents Dis. 1994 Feb;3(1):9-28 [7952927.001]
  • [Cites] Anal Biochem. 1994 Aug 1;220(2):360-6 [7978279.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] J Biochem. 1994 Oct;116(4):862-9 [7533763.001]
  • [Cites] Cell Immunol. 1995 Feb;160(2):165-72 [7536632.001]
  • [Cites] J Cell Sci. 1995 Jun;108 ( Pt 6):2511-23 [7673365.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Histopathology. 1996 Oct;29(4):337-46 [8910041.001]
  • [Cites] J Biol Chem. 1996 Nov 29;271(48):30587-94 [8940031.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • (PMID = 18045938.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / K02 AI049275; United States / NCI NIH HHS / CA / R01 CA091760; United States / NCI NIH HHS / CA / CA91760; United States / NIAID NIH HHS / AI / K02-AI49275
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 0 / Receptors, Virus; 0 / Viral Envelope Proteins; 0 / glycoprotein B, human herpesvirus 8
  • [Other-IDs] NLM/ PMC2224453
  •  go-up   go-down


59. Hagen T: Characterization of the interaction between latency-associated nuclear antigen and glycogen synthase kinase 3beta. J Virol; 2009 Jun;83(12):6312-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The latency-associated nuclear antigen (LANA) of Karposi's sarcoma-associated herpesvirus has been reported to interact with glycogen synthase kinase 3beta (GSK-3beta) and regulate its activity, leading to inhibition of GSK-3-dependent beta-catenin degradation.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2007 Oct;81(19):10413-23 [17634230.001]
  • [Cites] J Virol. 2007 Oct;81(19):10451-9 [17634226.001]
  • [Cites] FEBS Lett. 2001 Nov 2;507(3):288-94 [11696357.001]
  • [Cites] Cell. 2002 Mar 22;108(6):837-47 [11955436.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1066-76 [12000790.001]
  • [Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]
  • [Cites] J Virol. 2003 Jul;77(14):8019-30 [12829841.001]
  • [Cites] EMBO J. 1997 Feb 3;16(3):441-50 [9034327.001]
  • [Cites] Cell. 1998 Jun 12;93(6):1031-41 [9635432.001]
  • [Cites] Anal Biochem. 1998 Nov 1;264(1):124-7 [9784196.001]
  • [Cites] FEBS Lett. 1999 Sep 17;458(2):247-51 [10481074.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30419-23 [10521419.001]
  • [Cites] J Virol. 2005 Aug;79(16):10429-41 [16051835.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):9971-6 [16476742.001]
  • [Cites] J Virol. 2006 Aug;80(16):7965-75 [16873253.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e116 [17069461.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;312:101-36 [17089795.001]
  • [Cites] J Biol Chem. 2007 Jun 8;282(23):17032-40 [17439941.001]
  • [Cites] Virology. 2007 Aug 1;364(2):317-29 [17434559.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):4979-86 [17310999.001]
  • [Cites] J Cell Biol. 2000 Feb 21;148(4):691-702 [10684251.001]
  • (PMID = 19321622.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / beta Catenin; 0 / latency-associated nuclear antigen; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3
  • [Other-IDs] NLM/ PMC2687375
  •  go-up   go-down


60. Tuomisto J, Pekkanen J, Kiviranta H, Tukiainen E, Vartiainen T, Viluksela M, Tuomisto JT: Dioxin cancer risk--example of hormesis? Dose Response; 2005;3(3):332-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A recent case-control study implied an inverse correlation between the measured body burden of dioxins (polychlorinated dibenzo-p-dioxins and polychlorinated dibenzofurans, PCDD/F) and the risk of soft tissue sarcoma in normal population exposed to dioxins mainly via food.
  • Cases were 110 soft-tissue sarcoma patients undergoing surgery for their disease, and referents were 227 patients operated for appendicitis.
  • The highest risk of sarcoma was found in the septile with the lowest body burden of sum WHO-TEq, and the differences of septiles 2 and 6 from septile 1 were statistically significant.
  • If soft sarcoma risk is true at high occupational levels of dioxins, the provocative result suggests that a possibility of a J-shaped dose-response curve should be taken into consideration and studied further.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Appl Pharmacol. 1978 Nov;46(2):279-303 [734660.001]
  • [Cites] Regul Toxicol Pharmacol. 1992 Jun;15(3):245-52 [1509118.001]
  • [Cites] Toxicol Appl Pharmacol. 1992 May;114(1):118-26 [1585364.001]
  • [Cites] N Engl J Med. 1991 Jan 24;324(4):212-8 [1985242.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1982;22:517-54 [6282188.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):779-86 [10328108.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1999;39:103-25 [10331078.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Aug 1;174(3):216-24 [11485382.001]
  • [Cites] Chem Biol Interact. 2002 Sep 20;141(1-2):131-60 [12213389.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:233-60 [12359864.001]
  • [Cites] Int J Cancer. 2004 Mar 1;108(6):893-900 [14712494.001]
  • [Cites] Food Addit Contam. 2001 Nov;18(11):945-53 [11665735.001]
  • [Cites] Fundam Appl Toxicol. 1990 Apr;14(3):532-41 [2111257.001]
  • [Cites] Teratology. 1990 Jan;41(1):71-84 [2305375.001]
  • [Cites] J Toxicol Environ Health. 1989;27(2):165-71 [2733058.001]
  • [Cites] Toxicol Appl Pharmacol. 1989 Jun 15;99(2):287-301 [2734792.001]
  • [Cites] Carcinogenesis. 1987 Oct;8(10):1491-9 [2888545.001]
  • [Cites] Science. 1988 Jul 15;241(4863):334-6 [3133768.001]
  • [Cites] Pharmacol Rev. 1994 Dec;46(4):483-549 [7899475.001]
  • [Cites] Toxicology. 1993 Jul 11;81(1):1-13 [8367879.001]
  • [Cites] J Toxicol Environ Health. 1996 Mar;47(4):363-78 [8600289.001]
  • [Cites] Chemosphere. 1997 Jun;34(12):2571-83 [9204541.001]
  • [Cites] Food Addit Contam. 1997 May-Jun;14(4):355-66 [9205564.001]
  • [Cites] Epidemiology. 1997 Nov;8(6):646-52 [9345664.001]
  • [Cites] Food Addit Contam. 2000 Apr;17(4):241-59 [10912239.001]
  • [Cites] Food Addit Contam. 2000 Apr;17(4):261-6 [10912240.001]
  • [Cites] Food Addit Contam. 2000 Apr;17(4):303-16 [10912244.001]
  • [Cites] Food Addit Contam. 2000 Apr;17(4):317-24 [10912245.001]
  • [Cites] Food Addit Contam. 2000 Apr;17(4):325-33 [10912246.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6911-20 [11156390.001]
  • (PMID = 18648613.001).
  • [ISSN] 1559-3258
  • [Journal-full-title] Dose-response : a publication of International Hormesis Society
  • [ISO-abbreviation] Dose Response
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2475943
  • [Keywords] NOTNLM ; PCB / TCDD / body burden / cancer extrapolation / case-control study / dioxin / environmental exposure / individual exposure measurement / risk assessment / soft tissue sarcoma
  •  go-up   go-down


61. Zijenah LS, Kadzirange G, Madzime S, Borok M, Mudiwa C, Tobaiwa O, Mucheche M, Rusakaniko S, Katzenstein DA: Affordable flow cytometry for enumeration of absolute CD4+ T-lymphocytes to identify subtype C HIV-1 infected adults requiring antiretroviral therapy (ART) and monitoring response to ART in a resource-limited setting. J Transl Med; 2006 Aug 14;4:33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-five specimens were collected from AIDS patients enrolled in an ongoing Kaposi Sarcoma (KS) study to investigate impact of ART on KS progression.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1999 Sep;106(4):1059-62 [10520014.001]
  • [Cites] Cytometry. 2000 Dec 15;42(6):327-46 [11135287.001]
  • [Cites] AIDS. 2003 Oct 17;17(15):2201-8 [14523277.001]
  • [Cites] J Immunol Methods. 1996 Sep 9;195(1-2):103-12 [8814325.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 May 1;39(1):32-7 [15851911.001]
  • [Cites] Clin Diagn Lab Immunol. 2005 Dec;12(12):1416-24 [16339065.001]
  • [Cites] Lancet. 1986 Feb 8;1(8476):307-10 [2868172.001]
  • [Cites] Antivir Ther. 2004 Jun;9(3):395-405 [15259902.001]
  • (PMID = 16907973.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI060399
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1586214
  •  go-up   go-down


62. Spadavecchia S, Gonzalez-Lopez O, Carroll KD, Palmeri D, Lukac DM: Convergence of Kaposi's sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signaling pathway in coinfected cells. J Virol; 2010 Oct;84(20):10488-500
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Convergence of Kaposi's sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signaling pathway in coinfected cells.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiologic agent of primary effusion lymphoma (PEL).

  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1997 Nov 3;16(21):6478-85 [9351829.001]
  • [Cites] Blood. 1998 Feb 1;91(3):747-55 [9446632.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2835-44 [9566902.001]
  • [Cites] Oncogene. 1998 Apr 2;16(13):1731-42 [9582021.001]
  • [Cites] J Gen Virol. 1998 Jun;79 ( Pt 6):1445-52 [9634087.001]
  • [Cites] Dev Biol. 1999 Sep 1;213(1):33-53 [10452845.001]
  • [Cites] Virology. 1999 Sep 15;262(1):18-30 [10489337.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] Science. 1999 Oct 8;286(5438):300-3 [10514374.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Virol. 2005 Nov;79(22):14371-82 [16254371.001]
  • [Cites] Blood. 2006 Jan 1;107(1):277-84 [16150942.001]
  • [Cites] J Virol. 2006 Oct;80(19):9697-709 [16973574.001]
  • [Cites] Physiol Rev. 2007 Jan;87(1):99-163 [17237344.001]
  • [Cites] J Virol. 2007 Jun;81(11):6068-78 [17376914.001]
  • [Cites] J Virol. 2007 Jun;81(11):5788-806 [17392367.001]
  • [Cites] Anal Biochem. 2007 Jul 15;366(2):197-206 [17512890.001]
  • [Cites] J Virol. 2007 Aug;81(16):8451-67 [17537858.001]
  • [Cites] J Virol. 2007 Dec;81(24):13299-314 [17913801.001]
  • [Cites] PLoS One. 2008;3(2):e1569 [18253508.001]
  • [Cites] J Virol. 2008 Nov;82(21):10709-23 [18715905.001]
  • [Cites] J Virol. 2009 May;83(10):5014-27 [19264782.001]
  • [Cites] Dev Cell. 2009 May;16(5):633-47 [19460341.001]
  • [Cites] J Virol. 1999 Dec;73(12):10525-30 [10559372.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):401-9 [10830748.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] J Virol. 2001 Mar;75(5):2033-40 [11160707.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1195-203 [11031256.001]
  • [Cites] J Virol. 2001 Apr;75(8):3537-46 [11264343.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Virol. 1999 Apr;73(4):2770-80 [10074124.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):16085-96 [10347160.001]
  • [Cites] J Virol. 2001 Jul;75(13):5899-912 [11390591.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3694-704 [12446712.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] Blood. 2004 Jan 1;103(1):313-6 [12969959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):141-6 [14691250.001]
  • [Cites] J Virol. 2004 Apr;78(8):3941-52 [15047810.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2681-93 [14767477.001]
  • [Cites] J Exp Med. 1984 May 1;159(5):1554-9 [6325575.001]
  • [Cites] J Exp Med. 1990 Jul 1;172(1):61-8 [2162905.001]
  • [Cites] J Virol. 1992 Nov;66(11):6496-501 [1404600.001]
  • [Cites] J Biol Chem. 1992 Dec 5;267(34):24157-60 [1332946.001]
  • [Cites] J Exp Med. 1993 Mar 1;177(3):763-74 [8382256.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] EMBO J. 1995 Jan 3;14(1):88-96 [7828599.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]
  • [Cites] Cell. 1995 Feb 10;80(3):389-99 [7859281.001]
  • [Cites] J Virol. 1995 May;69(5):2968-76 [7707523.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Nature. 1995 Sep 28;377(6547):355-8 [7566092.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] EMBO J. 1996 Jan 15;15(2):375-82 [8617212.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] Lancet. 1996 Oct 26;348(9035):1133-8 [8888167.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Cytometry. 1996 Dec 1;25(4):333-40 [8946140.001]
  • [Cites] Oncogene. 1996 Nov 21;13(10):2243-54 [8950992.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):7070-8 [9003782.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1186-91 [9242551.001]
  • [Cites] Development. 1997 Oct;124(20):4133-41 [9374409.001]
  • (PMID = 20686042.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI078138; United States / NIAID NIH HHS / AI / AI 078138
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / DNA Primers; 0 / EBNA-2 protein, Human herpesvirus 4; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Immediate-Early Proteins; 0 / Immunoglobulin J Recombination Signal Sequence-Binding Protein; 0 / Receptors, Notch; 0 / Rta protein, Human herpesvirus 8; 0 / Trans-Activators; 0 / Viral Matrix Proteins; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2950570
  •  go-up   go-down


63. Codrington R, Pannell R, Forster A, Drynan LF, Daser A, Lobato N, Metzler M, Rabbitts TH: The Ews-ERG fusion protein can initiate neoplasia from lineage-committed haematopoietic cells. PLoS Biol; 2005 Aug;3(8):e242
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The EWS-ERG fusion protein is found in human sarcomas with the chromosomal translocation t(21;22)(q22;q12), where the translocation is considered to be an initiating event in sarcoma formation within uncommitted mesenchymal cells, probably long-lived progenitors capable of self renewal.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Comp Immunol. 2003 Jan;27(1):55-77 [12477501.001]
  • [Cites] EMBO J. 1999 Jul 1;18(13):3564-74 [10393173.001]
  • [Cites] Cancer Cell. 2003 May;3(5):449-58 [12781363.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):10002-7 [12890867.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9003-13 [14645513.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3029-35 [14701873.001]
  • [Cites] Genes Dev. 2004 May 1;18(9):965-74 [15132992.001]
  • [Cites] Curr Opin Oncol. 2004 Jul;16(4):342-54 [15187889.001]
  • [Cites] Anal Biochem. 1983 Jul 1;132(1):6-13 [6312838.001]
  • [Cites] Cell. 1984 Jul;37(3):1101-10 [6611207.001]
  • [Cites] Cell. 1986 Apr 25;45(2):237-46 [2938743.001]
  • [Cites] Nature. 1989 Mar 23;338(6213):350-2 [2493585.001]
  • [Cites] Nature. 1992 Sep 10;359(6391):162-5 [1522903.001]
  • [Cites] Leukemia. 1993 Apr;7(4):653-8 [8464245.001]
  • [Cites] Nature. 1993 Jun 17;363(6430):640-4 [8510758.001]
  • [Cites] Nat Genet. 1993 Jun;4(2):175-80 [7503811.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):341-5 [8401579.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10280-4 [8234289.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):146-51 [8162068.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2865-8 [8187069.001]
  • [Cites] Cell. 1994 Jul 15;78(1):45-57 [8033210.001]
  • [Cites] Nature. 1994 Nov 10;372(6502):143-9 [7969446.001]
  • [Cites] Oncogene. 1994 Dec;9(12):3717-29 [7970732.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Dec;11(4):256-62 [7533529.001]
  • [Cites] Oncogene. 1995 Mar 16;10(6):1229-34 [7700648.001]
  • [Cites] Oncogene. 1996 Jan 18;12(2):229-35 [8570200.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Feb 15;219(2):608-12 [8605035.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):531-3 [15607956.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):587-96 [15607963.001]
  • [Cites] Nat Methods. 2005 Jan;2(1):27-30 [15782166.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):311-21 [15803157.001]
  • [Cites] EMBO Rep. 2000 Aug;1(2):127-32 [11265751.001]
  • [Cites] EMBO Rep. 2000 Aug;1(2):133-9 [11265752.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5695-707 [11607819.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5747-54 [11607824.001]
  • [Cites] Blood. 2002 Jul 1;100(1):246-58 [12070034.001]
  • [Cites] Dev Cell. 2002 Jul;3(1):137-47 [12110174.001]
  • [Cites] Curr Opin Oncol. 2002 Jul;14(4):412-9 [12130926.001]
  • [Cites] Dev Comp Immunol. 2002 Oct;26(8):697-705 [12206833.001]
  • [Cites] Oncogene. 1996 Feb 1;12(3):489-94 [8637704.001]
  • [Cites] Cell. 1996 Jun 14;85(6):853-61 [8681380.001]
  • [Cites] Oncogene. 1997 Mar 13;14(10):1159-64 [9121764.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] Immunity. 1997 Nov;7(5):601-7 [9390684.001]
  • [Cites] Oncogene. 1998 Apr 16;16(15):1973-9 [9591781.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Immunity. 1999 May;10(5):537-46 [10367899.001]
  • [Cites] Cancer Genet Cytogenet. 2003 May;143(1):1-31 [12742153.001]
  • (PMID = 15974803.001).
  • [ISSN] 1545-7885
  • [Journal-full-title] PLoS biology
  • [ISO-abbreviation] PLoS Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EWS-ERG fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / Viral Proteins; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  • [Other-IDs] NLM/ PMC1159166
  •  go-up   go-down


64. Ramasamy P, Md Nor A, Kamil NA, Harun N, Yusof MM, Md Hassan MZ: Perineal myxoid liposarcomas: a case report and literature review. Malays J Med Sci; 2010 Oct;17(4):62-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We introduce an unusual case of a myxoid liposarcoma presenting as a large perineal swelling occupying the para-rectal and para-anal spaces in a 49-year-old male patient.
  • The diagnosis, management, and prognosis of myxoid liposarcoma are discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22135563.001).
  • [ISSN] 2180-4303
  • [Journal-full-title] The Malaysian journal of medical sciences : MJMS
  • [ISO-abbreviation] Malays J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Malaysia
  • [Other-IDs] NLM/ PMC3216183
  • [Keywords] NOTNLM ; myxoid liposarcoma / oncology / perineum / soft tissue sarcoma / surgery / tomography
  •  go-up   go-down


65. Kim JY, Cho YM, Ro JY: Prostatic stromal sarcoma with rhabdoid features. Ann Diagn Pathol; 2010 Dec;14(6):453-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic stromal sarcoma with rhabdoid features.
  • A 31-year-old man presented with a 4-month history of voiding difficulty and anal pain.
  • A needle biopsy was diagnosed as an unclassified spindle cell sarcoma, and 2 cycles of adriamycin-based neoadjuvant chemotherapy were given, followed by radical prostatectomy.
  • The prostatectomy specimen revealed a high-grade sarcoma with fascicles of highly cellular spindle cells and numerous mitoses with hemorrhage and necrosis.
  • The tumor showed an aggressive clinical behavior with a short-term survival (7 months after diagnosis).
  • [MeSH-major] Prostatic Neoplasms / pathology. Rhabdoid Tumor / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21074696.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Receptors, Progesterone; 0 / Vimentin
  •  go-up   go-down


66. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S, Swiss HIV Cohort: Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst; 2005 Mar 16;97(6):425-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Highly elevated SIRs were confirmed in persons infected with HIV for Kaposi sarcoma (KS) (SIR = 192, 95% confidence interval [CI] = 170 to 217) and non-Hodgkin lymphoma (SIR = 76.4, 95% CI = 66.5 to 87.4).
  • Statistically significantly elevated SIRs were also observed for anal cancer (SIR = 33.4, 95% CI = 10.5 to 78.6); Hodgkin lymphoma (SIR = 17.3, 95% CI = 10.2 to 27.4); cancers of the cervix (SIR = 8.0, 95% CI = 2.9 to 17.4); liver (SIR = 7.0, 95% CI = 2.2 to 16.5); lip, mouth, and pharynx (SIR = 4.1, 95% CI = 2.1 to 7.4); trachea, lung, and bronchus (SIR = 3.2, 95% CI = 1.7 to 5.4); and skin, nonmelanomatous (SIR = 3.2, 95% CI = 2.2 to 4.5).
  • [MeSH-minor] Adult. Aged. Cohort Studies. Confounding Factors (Epidemiology). Female. Humans. Incidence. Lymphocyte Count. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology. Male. Medical Record Linkage. Middle Aged. Odds Ratio. Papillomaviridae. Prospective Studies. Registries. Research Design. Risk Assessment. Risk Factors. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / virology. Switzerland / epidemiology. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / virology


67. Nadal SR, Manzione CR, Horta SH: Comparison of perianal diseases in HIV-positive patients during periods before and after protease inhibitors use: what changed in the 21st century. Dis Colon Rectum; 2008 Oct;51(10):1491-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In Group 1, the most common diseases were condylomas (24.7 percent), ulcers (21.8 percent), and anal fistulas (19.7 percent).
  • Tumors occurred in 2.5 percent, with Kaposi's sarcoma in 51.1 percent, and squamous-cell carcinoma in 27.6 percent.
  • The tumor incidence was 1.8 percent, with squamous-cell carcinoma in 59.4 percent and Kaposi's sarcoma in 23.2 percent.
  • Changes in incidence were statistically significant for the increase in condylomas and fissures, and for the decrease in ulcers, fistulas, and Kaposi's sarcoma among Group 2 patients.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670819.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protease Inhibitors
  •  go-up   go-down


68. Mansouri M, Rose PP, Moses AV, Früh K: Remodeling of endothelial adherens junctions by Kaposi's sarcoma-associated herpesvirus. J Virol; 2008 Oct;82(19):9615-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remodeling of endothelial adherens junctions by Kaposi's sarcoma-associated herpesvirus.
  • We now demonstrate that the transmembrane ubiquitin ligase K5/MIR-2 of Kaposi's sarcoma-associated herpesvirus targets VE-cadherin for ubiquitin-mediated destruction, thus disturbing EC adhesion.
  • Our data represent the first example of a viral protein targeting adherens junction proteins and suggest that K5 contributes to EC proliferation, vascular leakage, and the reprogramming of the EC proteome during Kaposi's sarcoma tumorigenesis.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19199-208 [12626512.001]
  • [Cites] J Cell Biol. 2003 May 26;161(4):793-804 [12771128.001]
  • [Cites] Cell Biochem Biophys. 2003;38(3):305-22 [12794270.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] J Virol. 2003 Jul;77(14):8019-30 [12829841.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] J Virol. 2003 Sep;77(17):9669-84 [12915579.001]
  • [Cites] Annu Rev Microbiol. 2003;57:609-39 [14527293.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):756-67 [14570040.001]
  • [Cites] J Virol. 2003 Nov;77(22):12276-84 [14581564.001]
  • [Cites] J Virol. 2004 Feb;78(3):1109-20 [14722266.001]
  • [Cites] J Biol Chem. 2004 Feb 20;279(8):6526-33 [14660654.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] BMC Cancer. 2003 Mar 18;3:7 [12697073.001]
  • [Cites] Thromb Haemost. 2005 Jun;93(6):1041-6 [15968386.001]
  • [Cites] Science. 2005 Jul 1;309(5731):127-30 [15994556.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6617-25 [16007161.001]
  • [Cites] Eur J Histochem. 2005 Jul-Sep;49(3):273-84 [16216813.001]
  • [Cites] J Virol. 2005 Nov;79(22):14371-82 [16254371.001]
  • [Cites] J Virol. 2005 Dec;79(24):15099-106 [16306581.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1932-40 [16601245.001]
  • [Cites] J Virol. 2006 Nov;80(21):10497-505 [16920823.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;312:211-44 [17089799.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e107 [17238276.001]
  • [Cites] Cell Cycle. 2004 May;3(5):571-3 [15107603.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1683-93 [15185310.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):683-5 [15220917.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • [Cites] Cell. 2005 Dec 2;123(5):889-901 [16325582.001]
  • [Cites] Exp Cell Res. 2006 Feb 15;312(4):457-67 [16368435.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18431-6 [16344472.001]
  • [Cites] Oncol Rep. 2006 Feb;15(2):311-5 [16391847.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):51-9 [16377174.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):621-7 [16410791.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):659-67 [16256984.001]
  • [Cites] Sci STKE. 2006 May 16;2006(335):re4 [16705130.001]
  • [Cites] J Microbiol. 2006 Apr;44(2):217-25 [16728959.001]
  • [Cites] Histochem Cell Biol. 2006 Jul;126(1):17-26 [16416023.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):314-24 [16816383.001]
  • [Cites] J Virol. 2007 Mar;81(5):2117-27 [17166914.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):245-58 [17349582.001]
  • [Cites] Nat Rev Immunol. 2007 May;7(5):391-401 [17457345.001]
  • [Cites] J Virol. 2007 May;81(10):5079-90 [17329329.001]
  • [Cites] J Cell Biol. 2007 May 21;177(4):613-24 [17502423.001]
  • [Cites] J Virol. 2008 Apr;82(8):4184-9 [18272573.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2711-20 [7522639.001]
  • [Cites] J Immunol. 1994 Nov 15;153(10):4816-25 [7963547.001]
  • [Cites] Cancer Surv. 1995;24:129-40 [7553658.001]
  • [Cites] J Clin Pathol. 1995 Nov;48(11):1011-6 [8543622.001]
  • [Cites] Res Virol. 1996 Sep-Oct;147(5):267-75 [8880996.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] J Virol. 1997 Mar;71(3):1963-74 [9032328.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):929-38 [9060831.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14 [9482916.001]
  • [Cites] J Cell Biol. 1998 Mar 23;140(6):1475-84 [9508779.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] J Virol. 1999 Aug;73(8):6892-902 [10400787.001]
  • [Cites] Nat Med. 1999 Sep;5(9):1039-43 [10470081.001]
  • [Cites] Trends Cell Biol. 2004 Nov;14(11):589-93 [15519846.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(1):389-402 [15601859.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12758-65 [15695815.001]
  • [Cites] Am J Pathol. 2005 May;166(5):1515-22 [15855650.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1369-78 [15864354.001]
  • [Cites] Traffic. 2005 Jun;6(6):429-41 [15882441.001]
  • [Cites] J Virol. 2000 Jun;74(11):5300-9 [10799607.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6 [10859362.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8455-60 [10890918.001]
  • [Cites] Exp Cell Res. 2000 Aug 25;259(1):158-66 [10942588.001]
  • [Cites] Adv Cancer Res. 2001;80:51-82 [11034540.001]
  • [Cites] J Investig Dermatol Symp Proc. 2000 Dec;5(1):10-3 [11147668.001]
  • [Cites] J Gen Virol. 2001 May;82(Pt 5):1175-80 [11297692.001]
  • [Cites] J Clin Invest. 2001 Jun;107(12):1599-606 [11413168.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1251-69 [11423257.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3323-31 [11423982.001]
  • [Cites] Thromb Haemost. 2001 Jul;86(1):308-15 [11487019.001]
  • [Cites] Immunity. 2001 Oct;15(4):627-36 [11672544.001]
  • [Cites] J Virol. 2002 Mar;76(6):2912-23 [11861858.001]
  • [Cites] Anal Chem. 2002 Mar 15;74(6):1333-9 [11924593.001]
  • [Cites] Infect Immun. 2002 May;70(5):2605-13 [11953402.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] Virus Res. 2002 Dec;90(1-2):77-89 [12457964.001]
  • [Cites] Trends Cell Biol. 2003 Jan;13(1):7-12 [12480335.001]
  • [Cites] Cell Commun Adhes. 2002 Mar-Apr;9(2):103-15 [12487411.001]
  • [Cites] J Virol. 2003 Jan;77(2):1427-40 [12502858.001]
  • (PMID = 18667499.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / T32 AI07472; United States / NIAID NIH HHS / AI / R01 CA/AI 094011; United States / NCRR NIH HHS / RR / P51 RR000163; United States / NCI NIH HHS / CA / R01 CA094011-04; United States / NCI NIH HHS / CA / R01 CA99906; United States / NCRR NIH HHS / RR / P51 RR000163-496078; United States / NCI NIH HHS / CA / R01 CA099906; United States / NIAID NIH HHS / AI / T32 AI007472; United States / NCRR NIH HHS / RR / RR000163-496078; United States / NCI NIH HHS / CA / R01 CA094011; United States / NCI NIH HHS / CA / CA094011-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Catenins; 0 / Ubiquitin
  • [Other-IDs] NLM/ PMC2546942
  •  go-up   go-down


69. Pickard MR, Green AR, Ellis IO, Caldas C, Hedge VL, Mourtada-Maarabouni M, Williams GT: Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res; 2009;11(4):R60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Functional expression cloning in two independent laboratories has identified Finkel-Biskis-Reilly murine sarcoma virus-associated ubiquitously expressed gene (Fau) as a novel apoptosis regulator and candidate tumour suppressor.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1754-9 [10677530.001]
  • [Cites] Carcinogenesis. 1999 Feb;20(2):311-6 [10069470.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):38953-6 [11038347.001]
  • [Cites] J Biol Chem. 2001 Jan 26;276(4):2780-5 [11054413.001]
  • [Cites] Cell Death Differ. 2003 Sep;10(9):1016-24 [12934076.001]
  • [Cites] Eur J Biochem. 2003 Oct;270(20):4052-8 [14519116.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8590-607 [14634621.001]
  • [Cites] Breast Cancer Res. 2004;6(5):R499-513 [15318932.001]
  • [Cites] Biochemistry. 1979 Nov 27;18(24):5294-9 [518835.001]
  • [Cites] Cell. 1991 Jun 28;65(7):1097-8 [1648446.001]
  • [Cites] Anal Biochem. 1992 Jun;203(2):352-6 [1384388.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1412-8 [8350365.001]
  • [Cites] Oncogene. 1993 Sep;8(9):2537-46 [8395683.001]
  • [Cites] J Cell Sci. 1999 Jun;112 ( Pt 11):1771-83 [10318769.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9419-26 [15543234.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1727-41 [15894099.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9751-61 [16266996.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] Nat Rev Cancer. 2006 Oct;6(10):776-88 [16990855.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S15-24 [17259554.001]
  • [Cites] Oncogene. 2007 Feb 26;26(9):1324-37 [17322918.001]
  • [Cites] Oncogene. 2007 Mar 1;26(10):1507-16 [16936776.001]
  • [Cites] Breast Cancer Res. 2007;9(1):R17 [17280616.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3637-43 [17530017.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):121-32 [18202696.001]
  • [Cites] J Cell Sci. 2008 Apr 1;121(Pt 7):939-46 [18354083.001]
  • [Cites] N Engl J Med. 2008 Jun 26;358(26):2796-803 [18579814.001]
  • [Cites] Oncogene. 2009 Jan 15;28(2):195-208 [18836484.001]
  • [Cites] Nat Med. 1996 Jul;2(7):811-4 [8673929.001]
  • [Cites] Nature. 1997 Nov 13;390(6656):180-4 [9367156.001]
  • [Cites] Oncogene. 2000 Aug 3;19(33):3774-81 [10949932.001]
  • (PMID = 19671159.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL2L14 protein, human; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Small Interfering; 0 / Ribosomal Proteins; 148266-62-0 / FAU protein, human; EC 2.7.1.- / MELK protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2750122
  •  go-up   go-down


70. Ambinder RF, Bhatia K, Martinez-Maza O, Mitsuyasu R: Cancer biomarkers in HIV patients. Curr Opin HIV AIDS; 2010 Nov;5(6):531-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: CD4 lymphocyte count is associated with primary central nervous system lymphoma (PCNSL), systemic non-Hodgkin's lymphoma (NHL) (except perhaps for Burkitt lymphoma), Kaposi's sarcoma, cervical cancer, and anal cancer.
  • HIV load is associated with Burkitt lymphoma and systemic NHL (but not PCNSL), with Kaposi's sarcoma and with anal cancer.
  • EBV and Kaposi's sarcoma-associated herpesvirus (KSHV) have not yet emerged as especially promising markers of risk for either lymphoma or Kaposi's sarcoma.